1. LiuL, JohnsonHL, CousensS, et al.Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet2012;379:2151. CrossRef

2. ImhoffB, MorseD, ShiferawB, et al.Burden of self‐reported acute diarrheal illness in FoodNet surveillance areas, 1998–1999. Clin Infect Dis2004;38(Suppl 3):S219. CrossRef

3. GouldLH, BoppC, StrockbineN, et al.Recommendations for diagnosis of shiga toxin–producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep2009;58(RR‐12):1.

4. HennessyTW, MarcusR, DeneenV, et al.Survey of physician diagnostic practices for patients with acute diarrhea: clinical and public health implications. Clin Infect Dis2004;38(Suppl 3):S203. CrossRef

5. PayneDC, VinjeJ, SzilagyiPG, et al.Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med2013;368:1121. CrossRef

6. FeeneySA, ArmstrongVJ, MitchellSJ, et al.Development and clinical validation of multiplex TaqMan(R) assays for rapid diagnosis of viral gastroenteritis. J Med Virol2011;83:1650. CrossRef

7. BrandaJA, LinTY, RosenbergES, et al.A rational approach to the stool ova and parasite examination. Clin Infect Dis2006;42:972. CrossRef

8. HanscheidT, ValadasE. Adequately performed stool ova and parasite examinations: is the best the enemy of the good?Clin Infect Dis2006;43:117. CrossRef

9. RosenblattJE. Clinical importance of adequately performed stool ova and parasite examinations. Clin Infect Dis2006;42:979. CrossRef

10. WeitzelT, DittrichS, MohlI, et al.Evaluation of seven commercial antigen detection tests for Giardia and Cryptosporidium in stool samples. Clin Microbiol Infect2006;12:656. CrossRef

11. HuichoL, CamposM, RiveraJ, et al.Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview. Pediatr Infect Dis J1996;15:486. CrossRef

12. KleinEJ, BosterDR, StappJR, et al.Diarrhea etiology in a Children's Hospital Emergency Department: a prospective cohort study. Clin Infect Dis2006;43:807. CrossRef

13. Centers for Disease Control and Prevention (CDC). Ongoing multistate outbreak of Escherichia coli serotype O157:H7 infections associated with consumption of fresh spinach–United States, September 2006. MMWR Morb Mortal Wkly Rep2006;55:1045.

14. PuylaertJB. Imaging and intervention in patients with acute right lower quadrant disease. Baillieres Clin Gastroenterol1995;9:37. CrossRef

15. MillerFH, MaJJ, ScholzFJ. Imaging features of enterohemorrhagic Escherichia coli colitis. AJR Am J Roentgenol2001;177:619. CrossRef

16. SakellarisG, TilemisS, CharissisG. Acute appendicitis in preschool‐age children. Eur J Pediatr2005;164:80. CrossRef

17. NussinovitchM, ShapiroRP, CohenAH, et al.Shigellosis complicated by perforated appendix. Pediatr Infect Dis J1993;12:352. CrossRef

18. KravitzGR, SmithK, WagstromL. Colonic necrosis and perforation secondary to Escherichia coli O157:H7 gastroenteritis in an adult patient without hemolytic uremic syndrome. Clin Infect Dis2002;35:e103. CrossRef

19. HelmsM, SimonsenJ, MolbakK. Foodborne bacterial infection and hospitalization: a registry‐based study. Clin Infect Dis2006;42:498. CrossRef

20. GoodmanLJ, TrenholmeGM, KaplanRL, et al.Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med1990;150:541. CrossRef

21. DrydenMS, GabbRJ, WrightSK. Empirical treatment of severe acute community‐acquired gastroenteritis with ciprofloxacin. Clin Infect Dis1996;22:1019. CrossRef

22. WistromJ, JertbornM, EkwallE, et al.Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo‐controlled study. Swedish Study Group. Ann Intern Med1992;117:202. CrossRef

23. NogueradoA, Garcia‐PoloI, IsasiaT, et al.Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomised, placebo‐controlled double‐blind clinical trial. J Antimicrob Chemother1995;36:665. CrossRef

24. NeillMA, OpalSM, HeelanJ, et al.Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med1991;114:195. CrossRef

25. DuPontHL, HaakeR, TaylorDN, et al.Rifaximin treatment of pathogen‐negative travelers' diarrhea. J Travel Med2007;14:16. CrossRef

26. EronenM, PutkonenH, HallikainenT, et al.Lethal gastroenteritis associated with clozapine and loperamide. Am J Psychiatry2003;160:2242. CrossRef

27. RiddleMS, ArnoldS, TribbleDR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta‐analysis. Clin Infect Dis2008;47:1007. CrossRef

28. TaylorDN, SanchezJL, CandlerW, et al.Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo‐controlled, randomized trial. Ann Intern Med1991;114:731. CrossRef

29. LiST, GrossmanDC, CummingsP. Loperamide therapy for acute diarrhea in children: systematic review and meta‐analysis. PLoS Med2007;4:e98. CrossRef

30. FreedmanSB, AdlerM, SeshadriR, et al.Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med2006;354:1698. CrossRef

31. CarterB, FedorowiczZ. Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta‐analysis and mixed treatment comparison in a Bayesian framework. BMJ Open2012;2:e000622. CrossRef

32. RamsookC, Sahagun‐CarreonI, KozinetzCA, et al.A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med2002;39:397. CrossRef

33. GirardMP, SteeleD, ChaignatCL, et al.A review of vaccine research and development: human enteric infections. Vaccine2006;24:2732. CrossRef

34. LawrenceGW, LehmannD, AnianG, et al.Impact of active immunisation against enteritis necroticans in Papua New Guinea. Lancet1990;336:1165. CrossRef

35. RichardsonV, Hernandez‐PichardoJ, Quintanar‐SolaresM, et al.Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med2010;362:299. CrossRef

36. NalinDR, CashRA, RahmanM, et al.Effect of glycine and glucose on sodium and water adsorption in patients with cholera. Gut1970;11:768. CrossRef

37. NalinDR, HirschhornN, GreenoughW3rd, et al.Clinical concerns about reduced‐osmolarity oral rehydration solution. JAMA2004;291:2632. CrossRef

38. OkhuysenPC, JiangZD, CarlinL, et al.Post‐diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol2004;99:1774. CrossRef

39. XinB, WangH. Multiple sequence variations in SLC5A1 gene are associated with glucose‐galactose malabsorption in a large cohort of Old Order Amish. Clin Genet2011;79:86. CrossRef

40. PetersonDE, LallaRV. Oral mucositis: the new paradigms. Curr Opin Oncol2010;22:318. CrossRef

41. LeeHJ, LeeSY, ChoiJE, et al.G protein beta3 subunit, interleukin‐10, and tumor necrosis factor‐alpha gene polymorphisms in Koreans with irritable bowel syndrome. Neurogastroenterol Motil2010;22:758. CrossRef

42. MingalaCN, KonnaiS, CruzLC, et al.Comparative moleculo‐immunological analysis of swamp‐ and riverine‐type water buffaloes responses. Cytokine2009;46:273. CrossRef

43. WangY, XuJM, ShenL, et al.[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. Zhonghua Zhong Liu Za Zhi2007;29:913.

44. FaruqueAS, MahalanabisD, HoqueSS, et al.The relationship between ABO blood groups and susceptibility to diarrhea due to Vibrio cholerae 0139. Clin Infect Dis1994;18:827. CrossRef

45. HahnKK, WolffJJ, KolesarJM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm2006;63:2211. CrossRef

46. JungAG, MathonyUA, BehreB, et al.Acrodermatitis enteropathica: an uncommon differential diagnosis in childhood – first description of a new sequence variant. J Dtsch Dermatol Ges2011;9:999.

47. KappelmanMD, GrandRJ. Does inflammatory bowel disease develop in infants?Inflamm Bowel Dis2008;14(Suppl 2):S6. CrossRef

48. SackRB, MyersLL, Almeido‐HillJ, et al.Enterotoxigenic Bacteroides fragilis: epidemiologic studies of its role as a human diarrhoeal pathogen. J Diarrhoeal Dis Res1992;10:4.

49. DuimstraJR, MyersLL, CollinsJE, et al.Enterovirulence of enterotoxigenic Bacteroides fragilis in gnotobiotic pigs. Vet Pathol1991;28:514. CrossRef

50. MyersLL, CollinsJE, ShoopDS. Ultrastructural lesions of enterotoxigenic Bacteroides fragilis in rabbits. Vet Pathol1991;28:336. CrossRef

51. RheeKJ, WuS, WuX, et al.Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild‐type C57BL/6 mice. Infect Immun2009;77:1708. CrossRef

52. FrancoAA, MundyLM, TrucksisM, et al.Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect Immun1997;65:1007.

53. DejeaC, WickE, SearsCL. Bacterial oncogenesis in the colon. Future Microbiol2013;8:445. CrossRef

54. DoganN, OzY, KocmanNU, et al.[Comparison of individual differences in the direct microscopic examination in the diagnosis of intestinal parasites]. Turkiye Parazitol Derg2012;36:211. CrossRef

55. ErdoganH, LeventB, ErdoganA, et al.[Investigation of verotoxigenic Escherichia coli O157:H7 incidence in gastroenteritis patients]. Mikrobiyol Bul2011;45:519.

56. AdachiJA, JiangZD, MathewsonJJ, et al.Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis2001;32:1706. CrossRef

57. YeY, ZhuD, WangK, et al.Clinical and electrophysiological features of the 2007 Guillain‐Barre syndrome epidemic in northeast China. Muscle Nerve2010;42:311. CrossRef

58. MshanaSE, JolobaM, KakoozaA, et al.Campylobacter spp among children with acute diarrhea attending Mulago hospital in Kampala–Uganda. Afr Health Sci2009;9:201.

59. GriffithsSL, SalmonRL, MasonBW, et al.Using the internet for rapid investigation of an outbreak of diarrhoeal illness in mountain bikers. Epidemiol Infect2010;138:1704. CrossRef

60. Sadkowska‐TodysM. [Campylobacteriosis in Poland in 2007]. Przegl Epidemiol2009;63:225.

61. ShahN, DuPontHL, RamseyDJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg2009;80:609.

62. SandbergM, BergsjoB, HofshagenM, et al.Risk factors for Campylobacter infection in Norwegian cats and dogs. Prev Vet Med2002;55:241. CrossRef

63. OwenRJ, SlaterE, TelfordD, et al.Subtypes of Campylobacter jejuni from sporadic cases of diarrhoeal disease at different locations in England are highly diverse. Eur J Epidemiol1997;13:837. CrossRef

64. StermerE, LubezkyA, PotasmanI, et al.Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis2006;43:898. CrossRef

65. PorterCK, GloorK, CashBD, et al.Risk of functional gastrointestinal disorders in U.S. military following self‐reported diarrhea and vomiting during deployment. Dig Dis Sci2011;56:3262. CrossRef

66. IlnyckyjA, BalachandraB, ElliottL, et al.Post‐traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol2003;98:596. CrossRef

67. BaatenGG, GeskusRB, KintJA, et al.Symptoms of infectious diseases in immunocompromised travelers: a prospective study with matched controls. J Travel Med2011;18:318. CrossRef

68. EricssonCD. Nonantimicrobial agents in the prevention and treatment of traveler's diarrhea. Clin Infect Dis2005;41(Suppl 8):S557. CrossRef

69. DuPontHL, JiangZD, OkhuysenPC, et al.Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. Clin Infect Dis2005;41(Suppl 8):S571. CrossRef

70. HeckJE, StaneckJL, CohenMB, et al.Prevention of travelers' diarrhea: ciprofloxacin versus trimethoprim/sulfamethoxazole in adult volunteers working in Latin America and the Caribbean. J Travel Med1994;1:136. CrossRef

71. DuPontHL, EricssonCD, FarthingMJ, et al.Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med2009;16:149. CrossRef

72. DupontHL, JiangZD, Belkind‐GersonJ, et al.Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol2007;5:451. CrossRef

73. TaylorDN, BourgeoisAL, EricssonCD, et al.A randomized, double‐blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg2006;74:1060.

74. Travelers' diarrhea.JAMA1985;253:2700. CrossRef

75. DuPontHL. Travelers' diarrhea: antimicrobial therapy and chemoprevention. Nat Clin Pract Gastroenterol Hepatol2005;2:191; quiz 1 p following 8. CrossRef

76. VentoS, CainelliF, CesarioF. Infections and thalassaemia. Lancet Infect Dis2006;6:226. CrossRef

77. Leirisalo‐RepoM. Reactive arthritis. Scand J Rheumatol2005;34:251. CrossRef

78. HarrisJB, KhanAI, LaRocqueRC, et al.Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun2005;73:7422. CrossRef

79. GabrielSE, BrigmanKN, KollerBH, et al.Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science1994;266:107. CrossRef

80. van de VosseE, AliS, de VisserAW, et al.Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). Hum Genet2005;118:138. CrossRef

81. FloresJ, OkhuysenPC. Genetics of susceptibility to infection with enteric pathogens. Curr Opin Infect Dis2009;22:471. CrossRef

82. MyersLL, FirehammerBD, ShoopDS, et al.Bacteroides fragilis: a possible cause of acute diarrheal disease in newborn lambs. Infect Immun1984;44:241.

83. PathelaP, HasanKZ, RoyE, et al.Enterotoxigenic Bacteroides fragilis‐associated diarrhea in children 0‐2 years of age in rural Bangladesh. J Infect Dis2005;191:1245. CrossRef

84. ZhangG, SvenungssonB, KarnellA, et al.Prevalence of enterotoxigenic Bacteroides fragilis in adult patients with diarrhea and healthy controls. Clin Infect Dis1999;29:590. CrossRef

85. SearsCL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev2009;22:349. CrossRef

86. WuS, PowellJ, MathioudakisN, et al.Bacteroides fragilis enterotoxin induces intestinal epithelial cell secretion of interleukin‐8 through mitogen‐activated protein kinases and a tyrosine kinase‐regulated nuclear factor‐kappaB pathway. Infect Immun2004;72:5832. CrossRef

87. WuS, MorinPJ, MaouyoD, et al.Bacteroides fragilis enterotoxin induces c‐Myc expression and cellular proliferation. Gastroenterology2003;124:392. CrossRef

88. ToprakNU, YagciA, GulluogluBM, et al.A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect2006;12:782. CrossRef

89. GoulasT, ArolasJL, Gomis‐RuthFX. Structure, function and latency regulation of a bacterial enterotoxin potentially derived from a mammalian adamalysin/ADAM xenolog. Proc Natl Acad Sci U S A2011;108:1856. CrossRef

90. RieglerM, LotzM, SearsC, et al.Bacteroides fragilis toxin 2 damages human colonic mucosa in vitro. Gut1999;44:504. CrossRef

91. SearsCL, IslamS, SahaA, et al.Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clin Infect Dis2008;47:797. CrossRef

92. SackRB, AlbertMJ, AlamK, et al.Isolation of enterotoxigenic Bacteroides fragilis from Bangladeshi children with diarrhea: a controlled study. J Clin Microbiol1994;32:960.

93. San JoaquinVH, GriffisJC, LeeC, et al.Association of Bacteroides fragilis with childhood diarrhea. Scand J Infect Dis1995;27:211. CrossRef

94. SkirrowMB. Campylobacter enteritis: a “new” disease. Br Med J1977;2:9. CrossRef

95. ButzlerJP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect2004;10:868. CrossRef

96. DekeyserP, Gossuin‐DetrainM, ButzlerJP, et al.Acute enteritis due to related vibrio: first positive stool cultures. J Infect Dis1972;125:390. CrossRef

97. SkirrowMB. John McFadyean and the centenary of the first isolation of Campylobacter species. Clin Infect Dis2006;43:1213. CrossRef

98. FriedmanCR, HoekstraRM, SamuelM, et al.Risk factors for sporadic Campylobacter infection in the United States: a case‐control study in FoodNet sites. Clin Infect Dis2004;38(Suppl 3):S285. CrossRef

99. DennoDM, ShaikhN, StappJR, et al.Diarrhea etiology in a pediatric emergency department: a case control study. Clin Infect Dis2012;55:897. CrossRef

100. ScallanE, GriffinPM, AnguloFJ, et al.Foodborne illness acquired in the United States–unspecified agents. Emerg Infect Dis2011;17:16. CrossRef

101. CokerAO, IsokpehiRD, ThomasBN, et al.Human campylobacteriosis in developing countries. Emerg Infect Dis2002;8:237. CrossRef

102. KramerJM, FrostJA, BoltonFJ, et al.Campylobacter contamination of raw meat and poultry at retail sale: identification of multiple types and comparison with isolates from human infection. J Food Prot2000;63:1654.

103. GiacoboniGI, ItohK, HirayamaK, et al.Comparison of fecal Campylobacter in calves and cattle of different ages and areas in Japan. J Vet Med Sci1993;55:555. CrossRef

104. NoormohamedA, FakhrMK. Incidence and antimicrobial resistance profiling of Campylobacter in retail chicken livers and gizzards. Foodborne Pathog Dis2012;9:617. CrossRef

105. RossAG, OldsGR, CrippsAW, et al.Enteropathogens and chronic illness in returning travelers. N Engl J Med2013;368:1817. CrossRef

106. EngbergJ, OnSL, HarringtonCS, et al.Prevalence of Campylobacter, Arcobacter, Helicobacter, and Sutterella spp. in human fecal samples as estimated by a reevaluation of isolation methods for Campylobacters. J Clin Microbiol2000;38:286.

107. NielsenHL, EngbergJ, EjlertsenT, et al.Clinical manifestations of Campylobacter concisus infection in children. Pediatr Infect Dis J2013;32:1194. CrossRef

108. KirkpatrickBD, TribbleDR. Update on human Campylobacter jejuni infections. Curr Opin Gastroenterol2011;27:1. CrossRef

109. Schrotz‐KingP, ProkhorovaTA, NielsenPN, et al.Campylobacter jejuni proteomics for new travellers' diarrhoea vaccines. Travel Med Infect Dis2007;5:106. CrossRef

110. WassenaarTM. Toxin production by Campylobacter spp. Clin Microbiol Rev1997;10:466.

111. BiswasD, ItohK, SasakawaC. Uptake pathways of clinical and healthy animal isolates of Campylobacter jejuni into INT‐407 cells. FEMS Immunol Med Microbiol2000;29:203. CrossRef

112. BouwmanLI, NiewoldP, van PuttenJP. Basolateral invasion and trafficking of Campylobacter jejuni in polarized epithelial cells. PLoS ONE2013;8:e54759. CrossRef

113. WatsonRO, GalanJE. Campylobacter jejuni survives within epithelial cells by avoiding delivery to lysosomes. PLoS Pathog2008;4:e14. CrossRef

114. AlbertMJ, HaridasS, SteerD, et al.Identification of a Campylobacter jejuni protein that cross‐reacts with cholera toxin. Infect Immun2007;75:3070. CrossRef

115. GatsosX, SteerDL, JunaidTA, et al.Application of protein purification methods for the enrichment of a cytotoxin from Campylobacter jejuni. BMC Microbiol2012;12:303. CrossRef

116. Lara‐TejeroM, GalanJE. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I‐like protein. Science2000;290:354. CrossRef

117. BouzariS, VargheseA. Cytolethal distending toxin (CLDT) production by enteropathogenic Escherichia coli (EPEC). FEMS Microbiol Lett1990;59:193. CrossRef

118. BlackRE, LevineMM, ClementsML, et al.Experimental Campylobacter jejuni infection in humans. J Infect Dis1988;157:472. CrossRef

119. RobinsonDA. Infective dose of Campylobacter jejuni in milk. Br Med J (Clin Res Ed)1981;282:1584. CrossRef

120. MahendranV, RiordanSM, GrimmMC, et al.Prevalence of Campylobacter species in adult Crohn's disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE2011;6:e25417. CrossRef

121. CampbellLK, HavensJM, ScottMA, et al.Molecular detection of Campylobacter jejuni in archival cases of acute appendicitis. Mod Pathol2006;19:1042.

122. MichalakDM, PerraultJ, GilchristMJ, et al.Campylobacter fetus ss. jejuni: a cause of massive lower gastrointestinal hemorrhage. Gastroenterology1980;79:742.

123. MeuwissenSG, BakkerPJ, RietraPJ. Acute ulceration of ileal stoma due to Campylobacter fetus subspecies jejuni. Br Med J (Clin Res Ed)1981;282:1362. CrossRef

124. SiegalD, SyedF, HamidN, et al.Campylobacter jejuni pancolitis mimicking idiopathic ulcerative colitis. Heart Lung2005;34:288. CrossRef

125. GaleazziM, PalombiL, MancinelliS, et al.Campylobacter infections and erythema nodosum. Eur J Epidemiol1986;2:80. CrossRef

126. HoskinsTW. Campylobacter enteritis and erythema nodosum. Br Med J (Clin Res Ed)1982;285:1661. CrossRef

127. Lopez‐BreaM, FontelosPM, BaqueroM, et al.Urticaria associated with campylobacter enteritis. Lancet1984;1:1354.

128. BretagAH, ArcherRS, AtkinsonHM, et al.Circadian urticaria: another campylobacter association. Lancet1984;1:954. CrossRef

129. SkirrowMB, JonesDM, SutcliffeE, et al.Campylobacter bacteraemia in England and Wales, 1981–91. Epidemiol Infect1993;110:567. CrossRef

130. Gerritsen van der HoopA, VeringaEM. Cholecystitis caused by Campylobacter jejuni. Clin Infect Dis1993;17:133. CrossRef

131. de BoisMH, SchoemakerMC, van der WerfSD, et al.Pancreatitis associated with Campylobacter jejuni infection: diagnosis by ultrasonography. BMJ1989;298:1004. CrossRef

132. SimorAE, KarmaliMA, JadavjiT, et al.Abortion and perinatal sepsis associated with campylobacter infection. Rev Infect Dis1986;8:397. CrossRef

133. AndrewsPI, KainerG, YongLC, et al.Glomerulonephritis, pulmonary hemorrhage and anemia associated with Campylobacter jejuni infection. Aust N Z J Med1989;19:721. CrossRef

134. HannuT, MattilaL, RautelinH, et al.Three cases of cardiac complications associated with Campylobacter jejuni infection and review of the literature. Eur J Clin Microbiol Infect Dis2005;24:619. CrossRef

135. KuwabaraS. Guillain‐Barre syndrome. Curr Neurol Neurosci Rep2007;7:57. CrossRef

136. HughesRA, HaddenRD, GregsonNA, et al.Pathogenesis of Guillain‐Barre syndrome. J Neuroimmunol1999;100:74. CrossRef

137. HughesRA, ReesJH. Clinical and epidemiologic features of Guillain‐Barre syndrome. J Infect Dis1997;176(Suppl 2):S92. CrossRef

138. IsraeliE, Agmon‐LevinN, BlankM, et al.Guillain‐Barre syndrome–a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol2012;42:121. CrossRef

139. TakigawaT, YasudaH, KikkawaR, et al.Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol1995;37:436. CrossRef

140. DedisteA, VandenbergO, VlaesL, et al.Evaluation of the ProSpecT Microplate Assay for detection of Campylobacter: a routine laboratory perspective. Clin Microbiol Infect2003;9:1085. CrossRef

141. KulkarniSP, LeverS, LoganJM, et al.Detection of campylobacter species: a comparison of culture and polymerase chain reaction based methods. J Clin Pathol2002;55:749. CrossRef

142. GranatoPA, ChenL, HolidayI, et al.Comparison of premier CAMPY enzyme immunoassay (EIA), ProSpecT Campylobacter EIA, and ImmunoCard STAT! CAMPY tests with culture for laboratory diagnosis of Campylobacter enteric infections. J Clin Microbiol2010;48:4022. CrossRef

143. CawthrawSA, FeldmanRA, SayersAR, et al.Long‐term antibody responses following human infection with Campylobacter jejuni. Clin Exp Immunol2002;130:101. CrossRef

144. AllosBM. Campylobacter jejuni Infections: update on emerging issues and trends. Clin Infect Dis2001;32:1201. CrossRef

145. Salazar‐LindoE, SackRB, Chea‐WooE, et al.Early treatment with erythromycin of Campylobacter jejuni‐associated dysentery in children. J Pediatr1986;109:355. CrossRef

146. PaiCH, GillisF, TuomanenE, et al.Erythromycin in treatment of Campylobacter enteritis in children. Am J Dis Child1983;137:286.

147. DuPontHL. Azithromycin for the self‐treatment of traveler's diarrhea. Clin Infect Dis2007;44:347. CrossRef

148. VukelicD, TrkuljaV, Salkovic‐PetrisicM. Single oral dose of azithromycin versus 5 days of oral erythromycin or no antibiotic in treatment of campylobacter enterocolitis in children: a prospective randomized assessor‐blind study. J Pediatr Gastroenterol Nutr2010;50:404.

149. van DoornPA, RutsL, JacobsBC. Clinical features, pathogenesis, and treatment of Guillain‐Barré syndrome. Lancet Neurol2008;7:939. CrossRef

150. BartlettJG, ChangTW, GurwithM, et al.Antibiotic‐associated pseudomembranous colitis due to toxin‐producing clostridia. N Engl J Med1978;298:531. CrossRef

151. AnanthakrishnanAN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol2011;8:17. CrossRef

152. WarnyM, PepinJ, FangA, et al.Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet2005;366:1079. CrossRef

153. BartlettJG, GerdingDN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis2008;46(Suppl 1):S12. CrossRef

154. PolageCR, SolnickJV, CohenSH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis2012;55:982. CrossRef

155. BarbutF, CorthierG, CharpakY, et al.Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med1996;156:1449. CrossRef

156. JohnsonS, ClabotsCR, LinnFV, et al.Nosocomial Clostridium difficile colonisation and disease. Lancet1990;336:97. CrossRef

157. JangiS, LamontJT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr2010;51:2. CrossRef

158. El FeghalyRE, StauberJL, TarrPI, et al.Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections. J Pediatr2013;163:1697. CrossRef

159. MadanR, JrWA. Immune responses to Clostridium difficile infection. Trends Mol Med2012;18:658. CrossRef

160. McDonaldLC, OwingsM, JerniganDB. Clostridium difficile infection in patients discharged from US short‐stay hospitals, 1996–2003. Emerg Infect Dis2006;12:409. CrossRef

161. RedelingsMD, SorvilloF, MascolaL. Increase in Clostridium difficile‐related mortality rates, United States, 1999–2004. Emerg Infect Dis2007;13:1417. CrossRef

162. BurckhardtF, FriedrichA, BeierD, et al.Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis2008;14:691. CrossRef

163. MillerBA, ChenLF, SextonDJ, et al.Comparison of the burdens of hospital‐onset, healthcare facility‐associated Clostridium difficile Infection and of healthcare‐associated infection due to methicillin‐resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol2011;32:387. CrossRef

164. LessaFC, GouldCV, McDonaldLC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis2012;55(Suppl 2):S65. CrossRef

165. MezoffEA, CohenMB. Acid suppression and the risk of Clostridium difficile infection. J Pediatr2013;163:627. CrossRef

166. DialS, DelaneyJA, BarkunAN, et al.Use of gastric acid‐suppressive agents and the risk of community‐acquired Clostridium difficile‐associated disease. JAMA2005;294:2989. CrossRef

167. AldeyabMA, KearneyMP, ScottMG, et al.An evaluation of the impact of antibiotic stewardship on reducing the use of high‐risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother2012;67:2988. CrossRef

168. PearSM, WilliamsonTH, BettinKM, et al.Decrease in nosocomial Clostridium difficile‐associated diarrhea by restricting clindamycin use. Ann Intern Med1994;120:272. CrossRef

169. AnandA, BasheyB, MirT, et al.Epidemiology, clinical manifestations, and outcome of Clostridium difficile‐associated diarrhea. Am J Gastroenterol1994;89:519.

170. ThomasC, StevensonM, WilliamsonDJ, et al.Clostridium difficile‐associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis2002;35:1457. CrossRef

171. McCuskerME, HarrisAD, PerencevichE, et al.Fluoroquinolone use and Clostridium difficile‐associated diarrhea. Emerg Infect Dis2003;9:730. CrossRef

172. McDonaldLC, KillgoreGE, ThompsonA, et al.An epidemic, toxin gene‐variant strain of Clostridium difficile. N Engl J Med2005;353:2433. CrossRef

173. LooVG, PoirierL, MillerMA, et al.A predominantly clonal multi‐institutional outbreak of Clostridium difficile‐associated diarrhea with high morbidity and mortality. N Engl J Med2005;353:2442. CrossRef

174. CloudJ, KellyCP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol2007;23:4.

175. LooVG, BourgaultAM, PoirierL, et al.Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med2011;365:1693. CrossRef

176. PokornM, RadselA, CizmanM, et al.Severe Clostridium difficile‐associated disease in children. Pediatr Infect Dis J2008;27:944. CrossRef

177. NylundCM, GoudieA, GarzaJM, et al.Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med2011;165:451. CrossRef

178. ClabotsCR, JohnsonS, OlsonMM, et al.Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis1992;166:561. CrossRef

179. McFarlandLV, MulliganME, KwokRY, et al.Nosocomial acquisition of Clostridium difficile infection. N Engl J Med1989;320:204. CrossRef

180. KyneL, WarnyM, QamarA, et al.Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med2000;342:390. CrossRef

181. MutoCA, PokrywkaM, ShuttK, et al.A large outbreak of Clostridium difficile‐associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol2005;26:273. CrossRef

182. McEllistremMC, CarmanRJ, GerdingDN, et al.A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis2005;40:265. CrossRef

183. PepinJ, ValiquetteL, AlaryME, et al.Clostridium difficile‐associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ2004;171:466. CrossRef

184. FeketyR. Guidelines for the diagnosis and management of Clostridium difficile‐associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol1997;92:739.

185. CohenSH, GerdingDN, JohnsonS, et al.Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol2010;31:431. CrossRef

186. SurawiczCM, BrandtLJ, BinionDG, et al.Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol2013;108:478; quiz 99. CrossRef

187. BouzaE, MunozP, AlonsoR. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect2005;11(Suppl 4):57. CrossRef

188. GerdingDN, JohnsonS, PetersonLR, et al.Clostridium difficile‐associated diarrhea and colitis. Infect Control Hosp Epidemiol1995;16:459. CrossRef

189. BarrosoLA, WangSZ, PhelpsCJ, et al.Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res1990;18:4004. CrossRef

190. DoveCH, WangSZ, PriceSB, et al.Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun1990;58:480.

191. JustI, SelzerJ, WilmM, et al.Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature1995;375:500. CrossRef

192. HechtG, PothoulakisC, LaMontJT, et al.Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest1988;82:1516. CrossRef

193. JustI, WilmM, SelzerJ, et al.The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem1995;270:13932. CrossRef

194. HechtG, KoutsourisA, PothoulakisC, et al.Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology1992;102:416.

195. MooreR, PothoulakisC, LaMontJT, et al.C. difficile toxin A increases intestinal permeability and induces Cl‐ secretion. Am J Physiol1990;259:G165.

196. RieglerM, SedivyR, PothoulakisC, et al.Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest1995;95:2004. CrossRef

197. GericB, CarmanRJ, RupnikM, et al.Binary toxin‐producing, large clostridial toxin‐negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis2006;193:1143. CrossRef

198. BoboLD, El FeghalyRE, ChenYS, et al.MAPK‐activated protein kinase 2 contributes to Clostridium difficile‐associated inflammation. Infect Immun2013;81:713. CrossRef

199. TriadafilopoulosG, PothoulakisC, WeissR, et al.Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology1989;97:1186.

200. KellyCP, BeckerS, LinevskyJK, et al.Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest1994;93:1257. CrossRef

201. QiuB, PothoulakisC, CastagliuoloI, et al.Participation of reactive oxygen metabolites in Clostridium difficile toxin A‐induced enteritis in rats. Am J Physiol1999;276:G485.

202. CastagliuoloI, KeatesAC, WangCC, et al.Clostridium difficile toxin A stimulates macrophage‐inflammatory protein‐2 production in rat intestinal epithelial cells. J Immunol1998;160:6039.

203. KuroseI, PothoulakisC, LaMontJT, et al.Clostridium difficile toxin A‐induced microvascular dysfunction. Role of histamine. J Clin Invest1994;94:1919. CrossRef

204. WershilBK, CastagliuoloI, PothoulakisC. Direct evidence of mast cell involvement in Clostridium difficile toxin A‐induced enteritis in mice. Gastroenterology1998;114:956. CrossRef

205. CastagliuoloI, KeatesAC, QiuB, et al.Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci U S A1997;94:4788. CrossRef

206. CastagliuoloI, WangCC, ValenickL, et al.Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest1999;103:843. CrossRef

207. BartlettJG. Clinical practice. Antibiotic‐associated diarrhea. N Engl J Med2002;346:334. CrossRef

208. BulusuM, NarayanS, ShetlerK, et al.Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol2000;95:3137. CrossRef

209. BartlettJG. Detection of Clostridium difficile infection. Infect Control Hosp Epidemiol2010;31(Suppl 1):S35. CrossRef

210. RousseauC, PoilaneI, De PontualL, et al.Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis2012;55:1209. CrossRef

211. BoltonRP, TaitSK, DearPR, et al.Asymptomatic neonatal colonisation by Clostridium difficile. Arch Dis Child1984;59:466. CrossRef

212. DontaST, MyersMG. Clostridium difficile toxin in asymptomatic neonates. J Pediatr1982;100:431. CrossRef

213. KellyCP, PothoulakisC, LaMontJT. Clostridium difficile colitis. N Engl J Med1994;330:257. CrossRef

214. KellyCP, LaMontJT. Clostridium difficile–more difficult than ever. N Engl J Med2008;359:1932. CrossRef

215. TedescoFJ, CorlessJK, BrownsteinRE. Rectal sparing in antibiotic‐associated pseudomembranous colitis: a prospective study. Gastroenterology1982;83:1259.

216. RubinMS, BodensteinLE, KentKC. Severe Clostridium difficile colitis. Dis Colon Rectum1995;38:350. CrossRef

217. AdamsSD, MercerDW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care2007;13:450. CrossRef

218. ChandraS, LattN, JariwalaU, et al.A cohort study for derivation and validation of a clinical prediction scale for hospital‐onset Clostridium difficile infection. Can J Gastroenterol2012;26:885.

219. OsmanKA, AhmedMH, HamadMA, et al.Emergency colectomy for fulminant Clostridium difficile colitis: striking the right balance. Scand J Gastroenterol2011;46:1222. CrossRef

220. KlipfelAA, ScheinM, FahoumB, et al.Acute abdomen and Clostridium difficile colitis: still a lethal combination. Dig Surg2000;17:160. CrossRef

221. MerzCS, KramerC, FormanM, et al.Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. J Clin Microbiol1994;32:1142.

222. PetersonLR, HolterJJ, ShanholtzerCJ, et al.Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test. Am J Clin Pathol1986;86:208.

223. CrobachMJ, DekkersOM, WilcoxMH, et al.European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile‐infection (CDI). Clin Microbiol Infect2009;15:1053. CrossRef

224. QuinnCD, SefersSE, BabikerW, et al.C. Diff Quik Chek complete enzyme immunoassay provides a reliable first‐line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol2010;48:603. CrossRef

225. GerdingDN, JohnsonS. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. Nat Rev Gastroenterol Hepatol2011;8:67. CrossRef

226. PetersonLR, RobicsekA. Does my patient have Clostridium difficile infection?Ann Intern Med2009;151:176. CrossRef

227. AslamS, MusherDM. An update on diagnosis, treatment, and prevention of Clostridium difficile‐associated disease. Gastroenterol Clin North Am2006;35:315. CrossRef

228. OlsonMM, ShanholtzerCJ, LeeJTJr, et al.Ten years of prospective Clostridium difficile‐associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol1994;15:371. CrossRef

229. SchutzeGE, WilloughbyRE. Clostridium difficile infection in infants and children. Pediatrics2013;131:196. CrossRef

230. TeasleyDG, GerdingDN, OlsonMM, et al.Prospective randomised trial of metronidazole versus vancomycin for Clostridium‐difficile‐associated diarrhoea and colitis. Lancet1983;2:1043. CrossRef

231. BoltonRP, CulshawMA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut1986;27:1169. CrossRef

232. FeketyR, SilvaJ, KauffmanC, et al.Treatment of antibiotic‐associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med1989;86:15. CrossRef

233. LouieTJ, MillerMA, MullaneKM, et al.Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med2011;364:422. CrossRef

234. LinskyA, GuptaK, HermosJA. Fidaxomicin for Clostridium difficile infection. N Engl J Med2011;364:1875; author reply 6. CrossRef

235. LowyI, MolrineDC, LeavBA, et al.Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med2010;362:197. CrossRef

236. BarbutF, RichardA, HamadiK, et al.Epidemiology of recurrences or reinfections of Clostridium difficile‐associated diarrhea. J Clin Microbiol2000;38:2386.

237. FigueroaI, JohnsonS, SambolSP, et al.Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis2012;55(Suppl 2):S104. CrossRef

238. ChiaJH, LaiHC, SuLH, et al.Molecular epidemiology of Clostridium difficile at a medical center in Taiwan: persistence of genetically clustering of A(−)B(+) isolates and increase of A(+)B(+) isolates. PLoS ONE2013;8:e75471. CrossRef

239. BrandtLJ, BorodyTJ, CampbellJ. Endoscopic fecal microbiota transplantation: “first‐line” treatment for severe clostridium difficile infection?J Clin Gastroenterol2011;45:655. CrossRef

240. BakkenJS, BorodyT, BrandtLJ, et al.Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol2011;9:1044. CrossRef

241. RussellG, KaplanJ, FerraroM, et al.Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics2010;126:e239. CrossRef

242. BrandtLJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol2013;108:177. CrossRef

243. KassamZ, LeeCH, YuanY, et al.Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta‐analysis. Am J Gastroenterol2013;108:500. CrossRef

244. BrandtLJ, AroniadisOC, MellowM, et al.Long‐term follow‐up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol2012;107:1079. CrossRef

245. HamiltonMJ, WeingardenAR, SadowskyMJ, et al.Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol2012;107:761. CrossRef

246. LeeCH. Multi‐Centre Trial of Fresh vs. Frozen‐and‐Thawed HBT (Fecal Transplant) for Recurrent CDI. ClinicalTrials.gov Identifier: NCT01398969. Available at: http://www.clinicaltrials.gov. Accessed June 2014.

247. BorodyTJ, BrandtLJ, ParamsothyS. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol2014;30:97. CrossRef

248. van NoodE, SpeelmanP, NieuwdorpM, et al.Fecal microbiota transplantation: facts and controversies. Curr Opin Gastroenterol2014;30:34. CrossRef

249. van NoodE, VriezeA, NieuwdorpM, et al.Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med2013;368:407. CrossRef

250. CollinsSM, SuretteM, BercikP. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol2012;10:735. CrossRef

251. BuccigrossiV, NicastroE, GuarinoA. Functions of intestinal microflora in children. Curr Opin Gastroenterol2013;29:31. CrossRef

252. VriezeA, Van NoodE, HollemanF, et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology2012;143:913. CrossRef

253. VriezeA, de GrootPF, KootteRS, et al.Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?Best Pract Res Clin Gastroenterol2013;27:127. CrossRef

254. Food and Drug Administration. Vaccines, Blood and Biologics. Available at: http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm357258.htm. Accessed July 2014.

255. MerriganMM, SambolSP, JohnsonS, et al.New approach to the management of Clostridium difficile infection: colonisation with non‐toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents2009;33(Suppl 1):S46. CrossRef

256. SambolSP, MerriganMM, TangJK, et al.Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis2002;186:1781. CrossRef

257. ChangJY, AntonopoulosDA, KalraA, et al.Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile‐associated diarrhea. J Infect Dis2008;197:435. CrossRef

258. LawleyTD, ClareS, WalkerAW, et al.Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog2012;8:e1002995. CrossRef

259. LandyJ, Al‐HassiHO, McLaughlinSD, et al.Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther2011;34:409. CrossRef

260. BrynestadS, GranumPE. Clostridium perfringens and foodborne infections. Int J Food Microbiol2002;74:195. CrossRef

261. GormleyFJ, LittleCL, RawalN, et al.A 17‐year review of foodborne outbreaks: describing the continuing decline in England and Wales (1992–2008). Epidemiol Infect2011;139:688. CrossRef

262. MurrellTG, WalkerPD. The pigbel story of Papua New Guinea. Trans R Soc Trop Med Hyg1991;85:119. CrossRef

263. MarooS, LamontJT. Recurrent clostridium difficile. Gastroenterology2006;130:1311. CrossRef

264. DupontHL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol2013;11:1216; quiz e73. CrossRef

265. LehrerS. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med2013;368:2144.

266. WenQ, McClaneBA. Detection of enterotoxigenic Clostridium perfringens type A isolates in American retail foods. Appl Environ Microbiol2004;70:2685. CrossRef

267. GrassJE, GouldLH, MahonBE. Epidemiology of foodborne disease outbreaks caused by Clostridium perfringens, United States, 1998–2010. Foodborne Pathog Dis2013;10:131. CrossRef

268. DaltonCB, GregoryJ, KirkMD, et al.Foodborne disease outbreaks in Australia, 1995 to 2000. Commun Dis Intell Q Rep2004;28:211.

269. SmithWP, McDonelJL. Clostridium perfringens type A: in vitro system for sporulation and enterotoxin synthesis. J Bacteriol1980;144:306.

270. WatsonDA, AndrewJH, BantingS, et al.Pig‐bel but no pig: enteritis necroticans acquired in Australia. Med J Aust1991;155:47.

271. LawrenceG, ShannF, FreestoneDS, et al.Prevention of necrotising enteritis in Papua New Guinea by active immunisation. Lancet1979;1:227. CrossRef

272. PetitL, GibertM, PopoffMR. Clostridium perfringens: toxinotype and genotype. Trends Microbiol1999;7:104. CrossRef

273. SkjelkvaleR, UemuraT. Experimental Diarrhoea in human volunteers following oral administration of Clostridium perfringens enterotoxin. J Appl Bacteriol1977;43:281. CrossRef

274. SarkerMR, CarmanRJ, McClaneBA. Inactivation of the gene (cpe) encoding Clostridium perfringens enterotoxin eliminates the ability of two cpe‐positive C. perfringens type A human gastrointestinal disease isolates to affect rabbit ileal loops. Mol Microbiol1999;33:946. CrossRef

275. CollieRE, McClaneBA. Evidence that the enterotoxin gene can be episomal in Clostridium perfringens isolates associated with non‐food‐borne human gastrointestinal diseases. J Clin Microbiol1998;36:30.

276. CornillotE, Saint‐JoanisB, DaubeG, et al.The enterotoxin gene (cpe) of Clostridium perfringens can be chromosomal or plasmid‐borne. Mol Microbiol1995;15:639. CrossRef

277. FujitaK, KatahiraJ, HoriguchiY, et al.Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin‐3, a tight junction integral membrane protein. FEBS Lett2000;476:258. CrossRef

278. VeshnyakovaA, ProtzeJ, RossaJ, et al.On the interaction of Clostridium perfringens enterotoxin with claudins. Toxins (Basel)2010;2:1336. CrossRef

279. ChakrabartiG, ZhouX, McClaneBA. Death pathways activated in CaCo‐2 cells by Clostridium perfringens enterotoxin. Infect Immun2003;71:4260. CrossRef

280. ChakrabartiG, McClaneBA. The importance of calcium influx, calpain and calmodulin for the activation of CaCo‐2 cell death pathways by Clostridium perfringens enterotoxin. Cell Microbiol2005;7:129. CrossRef

281. LawrenceG, WalkerPD. Pathogenesis of enteritis necroticans in Papula New Guinea. Lancet1976;1:125. CrossRef

282. ShaturskyO, BaylesR, RogersM, et al.Clostridium perfringens beta‐toxin forms potential‐dependent, cation‐selective channels in lipid bilayers. Infect Immun2000;68:5546. CrossRef

283. TwetenRK. Clostridium perfringens beta toxin and Clostridium septicum alpha toxin: their mechanisms and possible role in pathogenesis. Vet Microbiol2001;82:1. CrossRef

284. HallJA, GouldingJS, BeanNH, et al.Epidemiologic profiling: evaluating foodborne outbreaks for which no pathogen was isolated by routine laboratory testing: United States, 1982–9. Epidemiol Infect2001;127:381.

285. HannanMJ, HoqueMM. Intestinal obstruction in children due to segmental enteritis: experience in Chittagong, Bangladesh. Pediatr Surg Int2012;28:277. CrossRef

286. NataroJP, MaiV, JohnsonJ, et al.Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin Infect Dis2006;43:402. CrossRef

287. KarmaliMA, SteeleBT, PetricM, et al.Sporadic cases of haemolytic‐uraemic syndrome associated with faecal cytotoxin and cytotoxin‐producing Escherichia coli in stools. Lancet1983;1:619. CrossRef

288. RileyLW, RemisRS, HelgersonSD, et al.Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med1983;308:681. CrossRef

289. O'BrienAO, LivelyTA, ChenME, et al.Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet1983;1(8326):702.

290. CalderwoodSB, AuclairF, Donohue‐RolfeA, et al.Nucleotide sequence of the Shiga‐like toxin genes of Escherichia coli. Proc Natl Acad Sci U S A1987;84:4364. CrossRef

291. TarrPI, GordonCA, ChandlerWL. Shiga‐toxin‐producing Escherichia coli and haemolytic uraemic syndrome. Lancet2005;365:1073.

292. RajiMA, JiwaSF, MingaMU, et al.Escherichia coli 0157: H7 reservoir, transmission, diagnosis and the African situation: a review. East Afr Med J2003;80:271.

293. DuffellE, EspieE, NicholsT, et al.Investigation of an outbreak of E. coli O157 infections associated with a trip to France of schoolchildren from Somerset, England. Euro Surveill2003;8:81.

294. MakiDG. Don't eat the spinach–controlling foodborne infectious disease. N Engl J Med2006;355:1952. CrossRef

295. MatthewsL, LowJC, GallyDL, et al.Heterogeneous shedding of Escherichia coli O157 in cattle and its implications for control. Proc Natl Acad Sci U S A2006;103:547. CrossRef

296. MatthewsL, ReeveR, GallyDL, et al.Predicting the public health benefit of vaccinating cattle against Escherichia coli O157. Proc Natl Acad Sci U S A2013;110:16265. CrossRef

297. LingwoodCA. Shiga toxin receptor glycolipid binding. Pathology and utility. Methods Mol Med2003;73:165.

298. O'LoughlinEV, Robins‐BrowneRM. Effect of Shiga toxin and Shiga‐like toxins on eukaryotic cells. Microbes Infect2001;3:493. CrossRef

299. KovbasnjukO, MourtazinaR, BaibakovB, et al.The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci U S A2005;102:19087. CrossRef

300. LeeSY, LeeMS, CherlaRP, et al.Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell Microbiol2008;10:770. CrossRef

301. BitzanMM, WangY, LinJ, et al.Verotoxin and ricin have novel effects on preproendothelin‐1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest1998;101:372. CrossRef

302. SieglerRL, ObrigTG, PysherTJ, et al.Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol2003;18:92.

303. LouiseCB, ObrigTG. Specific interaction of Escherichia coli O157:H7‐derived Shiga‐like toxin II with human renal endothelial cells. J Infect Dis1995;172:1397. CrossRef

304. JelacicS, WobbeCL, BosterDR, et al.ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections. J Infect Dis2002;185:214. CrossRef

305. OstroffSM, TarrPI, NeillMA, et al.Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis1989;160:994. CrossRef

306. FriedrichAW, BielaszewskaM, ZhangWL, et al.Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis2002;185:74. CrossRef

307. Melton‐CelsaA, MohawkK, TeelL, et al.Pathogenesis of Shiga‐toxin producing escherichia coli. Curr Top Microbiol Immunol2012;357:67.

308. ScottME, Melton‐CelsaAR, O'BrienAD. Mutations in hns reduce the adherence of Shiga toxin‐producing E. coli 091:H21 strain B2F1 to human colonic epithelial cells and increase the production of hemolysin. Microb Pathog2003;34:155. CrossRef

309. SinclairJF, O'BrienAD. Intimin types alpha, beta, and gamma bind to nucleolin with equivalent affinity but lower avidity than to the translocated intimin receptor. J Biol Chem2004;279:33751. CrossRef

310. DeVinneyR, SteinM, ReinscheidD, et al.Enterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated. Infect Immun1999;67:2389.

311. HayashiT, MakinoK, OhnishiM, et al.Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K‐12. DNA Res2001;8:11. CrossRef

312. PernaNT, PlunkettG3rd, BurlandV, et al.Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature2001;409:529. CrossRef

313. LathemWW, BergsbakenT, WelchRA. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7. J Exp Med2004;199:1077. CrossRef

314. TorresAG, GironJA, PernaNT, et al.Identification and characterization of lpfABCC'DE, a fimbrial operon of enterohemorrhagic Escherichia coli O157:H7. Infect Immun2002;70:5416. CrossRef

315. JohnsonJR, JelacicS, SchoeningLM, et al.The IrgA homologue adhesin Iha is an Escherichia coli virulence factor in murine urinary tract infection. Infect Immun2005;73:965. CrossRef

316. BadeaL, DoughtyS, NichollsL, et al.Contribution of Efa1/LifA to the adherence of enteropathogenic Escherichia coli to epithelial cells. Microb Pathog2003;34:205. CrossRef

317. TatsunoI, HorieM, AbeH, et al.toxB gene on pO157 of enterohemorrhagic Escherichia coli O157:H7 is required for full epithelial cell adherence phenotype. Infect Immun2001;69:6660. CrossRef

318. CampelloneKG, RobbinsD, LeongJM. EspFU is a translocated EHEC effector that interacts with Tir and N‐WASP and promotes Nck‐independent actin assembly. Dev Cell2004;7:217. CrossRef

319. SilvestroL, CaputoM, BlancatoS, et al.Asymptomatic carriage of verocytotoxin‐producing Escherichia coli O157 in farm workers in Northern Italy. Epidemiol Infect2004;132:915. CrossRef

320. OstroffSM, KobayashiJM, LewisJH. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA1989;262:355. CrossRef

321. WongCS, JelacicS, HabeebRL, et al.The risk of the hemolytic‐uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med2000;342:1930. CrossRef

322. KleinEJ, StappJR, ClausenCR, et al.Shiga toxin‐producing Escherichia coli in children with diarrhea: a prospective point‐of‐care study. J Pediatr2002;141:172. CrossRef

323. JelacicJK, DamrowT, ChenGS, et al.Shiga toxin‐producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J Infect Dis2003;188:719. CrossRef

324. BrandtJR, FouserLS, WatkinsSL, et al.Escherichia coli O 157:H7‐associated hemolytic‐uremic syndrome after ingestion of contaminated hamburgers. J Pediatr1994;125:519. CrossRef

325. BrandtJR, JosephMW, FouserLS, et al.Cholelithiasis following Escherichia coli O157:H7‐associated hemolytic uremic syndrome. Pediatr Nephrol1998;12:222. CrossRef

326. RobsonWL, LeungAK, MontgomeryMD. Causes of death in hemolytic uremic syndrome. Child Nephrol Urol1991;11:228.

327. TapperD, TarrP, AvnerE, et al.Lessons learned in the management of hemolytic uremic syndrome in children. J Pediatr Surg1995;30:158. CrossRef

328. SassDA, ChopraKB, RegueiroMD. Pancreatitis and E. coli O157:H7 colitis without hemolytic uremic syndrome. Dig Dis Sci2003;48:415. CrossRef

329. MarshallJK, ThabaneM, GargAX, et al.Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology2006;131:445; quiz 660. CrossRef

330. MarshallJK, ThabaneM, GargAX, et al.Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut2010;59:605. CrossRef

331. Centers for Disease Control and Prevention (CDC). Importance of culture confirmation of shiga toxin‐producing Escherichia coli infection as illustrated by outbreaks of gastroenteritis–New York and North Carolina, 2005. MMWR Morb Mortal Wkly Rep2006;55:1042.

332. PaviaAT, NicholsCR, GreenDP, et al.Hemolytic‐uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr1990;116:544. CrossRef

333. CarterAO, BorczykAA, CarlsonJA, et al.A severe outbreak of Escherichia coli O157:H7–associated hemorrhagic colitis in a nursing home. N Engl J Med1987;317:1496. CrossRef

334. DundasS, ToddWT, StewartAI, et al.The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis2001;33:923. CrossRef

335. SafdarN, SaidA, GangnonRE, et al.Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta‐analysis. JAMA2002;288:996. CrossRef

336. IkedaK, IdaO, KimotoK, et al.Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol1999;52:357.

337. WongCS, MooneyJC, BrandtJR, et al.Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis2012;55:33. CrossRef

338. HickeyCA, BeattieTJ, CowiesonJ, et al.Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med2011;165:884. CrossRef

339. AkeJA, JelacicS, CiolMA, et al.Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics2005;115:e673. CrossRef

340. GargAX, SuriRS, BarrowmanN, et al.Long‐term renal prognosis of diarrhea‐associated hemolytic uremic syndrome: a systematic review, meta‐analysis, and meta‐regression. JAMA2003;290:1360. CrossRef

341. SieglerRL, MilliganMK, BurninghamTH, et al.Long‐term outcome and prognostic indicators in the hemolytic‐uremic syndrome. J Pediatr1991;118:195. CrossRef

342. TrachtmanH. HUS and TTP in Children. Pediatr Clin North Am2013;60:1513. CrossRef

343. TarrPI. Shiga toxin‐associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis. Kidney Int Suppl2009;112:S29. CrossRef

344. OguraY, OokaT, IguchiA, et al.Comparative genomics reveal the mechanism of the parallel evolution of O157 and non‐O157 enterohemorrhagic Escherichia coli. Proc Natl Acad Sci U S A2009;106:17939. CrossRef

345. BoketeTN, WhittamTS, WilsonRA, et al.Genetic and phenotypic analysis of Escherichia coli with enteropathogenic characteristics isolated from Seattle children. J Infect Dis1997;175:1382. CrossRef

346. KarchH, BohmH, SchmidtH, et al.Clonal structure and pathogenicity of Shiga‐like toxin‐producing, sorbitol‐fermenting Escherichia coli O157:H. J Clin Microbiol1993;31:1200.

347. PatonAW, SrimanoteP, TalbotUM, et al.A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med2004;200:35. CrossRef

348. PatonAW, BeddoeT, ThorpeCM, et al.AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature2006;443:548. CrossRef

349. From the Centers for Disease Control and Prevention. University outbreak of calcivirus infection mistakenly attributed to Shiga toxin‐producing Escherichia coli O157:H7–Virginia, 2000. JAMA2001;286:162.

350. ElliottEJ, Robins‐BrowneRM, O'LoughlinEV, et al.Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child2001;85:125. CrossRef

351. DeSN, BhattacharyaK, SarkarJK. A study of the pathogenicity of strains of Bacterium coli from acute and chronic enteritis. J Pathol Bacteriol1956;71:201. CrossRef

352. SackRB, GorbachSL, BanwellJG, et al.Enterotoxigenic Escherichia coli isolated from patients with severe cholera‐like disease. J Infect Dis1971;123:378. CrossRef

353. GorbachSL, KeanBH, EvansDG, et al.Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med1975;292:933. CrossRef

354. MersonMH, MorrisGK, SackDA, et al.Travelers' diarrhea in Mexico. A prospective study of physicians and family members attending a congress. N Engl J Med1976;294:1299. CrossRef

355. KeanBH, SchaffnerW, BrennanRW. The diarrhea of travelers. V. Prophylaxis with phthalylsulfathiazole and neomycin sulphate. JAMA1962;180:367. CrossRef

356. QadriF, SvennerholmAM, FaruqueAS, et al.Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev2005;18:465. CrossRef

357. Sjokvist OttsjoL, FlachCF, ClementsJ, et al.A double mutant heat‐labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun2013;81:1532. CrossRef

358. SteinslandH, Valentiner‐BranthP, GjessingHK, et al.Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet2003;362:286. CrossRef

359. RaoMC, OrellanaSA, FieldM, et al.Comparison of the biological actions of three purified heat‐stable enterotoxins: effects on ion transport and guanylate cyclase activity in rabbit ileum in vitro. Infect Immun1981;33:165.

360. ChanSK, GiannellaRA. Amino acid sequence of heat‐stable enterotoxin produced by Escherichia coli pathogenic for man. J Biol Chem1981;256:7744.

361. ThompsonMR, GiannellaRA. Revised amino acid sequence for a heat‐stable enterotoxin produced by an Escherichia coli strain (18D) that is pathogenic for humans. Infect Immun1985;47:834.

362. CurrieMG, FokKF, KatoJ, et al.Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A1992;89:947. CrossRef

363. HamraFK, ForteLR, EberSL, et al.Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A1993;90:10464. CrossRef

364. RomiH, CohenI, LandauD, et al.Meconium ileus caused by mutations in GUCY2C, encoding the CFTR‐activating guanylate cyclase 2C. Am J Hum Genet2012;90:893. CrossRef

365. TalA, CarmiR, Chai‐AmE, et al.Familial meconium ileus with normal sweat electrolytes. Clin Pediatr (Phila)1985;24:460. CrossRef

366. FiskerstrandT, ArshadN, HaukanesBI, et al.Familial diarrhea syndrome caused by an activating GUCY2C mutation. N Engl J Med2012;366:1586. CrossRef

367. RaoSS, QuigleyEM, ShiffSJ, et al.Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol2014;12:616. CrossRef

368. CastroJ, HarringtonAM, HughesPA, et al.Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase‐C and extracellular cyclic guanosine 3',5'‐monophosphate. Gastroenterology2013;145:1334. CrossRef

369. JohnstonJM, KurtzCB, MacdougallJE, et al.Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology2010;139:1877. CrossRef

370. IsideanSD, RiddleMS, SavarinoSJ, et al.A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine2011;29:6167. CrossRef

371. BoedekerEC. Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol2005;21:15.

372. SackRB, HirschhornN, BrownleeI, et al.Enterotoxigenic Escherichia‐coli‐associated diarrheal disease in Apache children. N Engl J Med1975;292:1041. CrossRef

373. BeattyME, AdcockPM, SmithSW, et al.Epidemic diarrhea due to enterotoxigenic Escherichia coli. Clin Infect Dis2006;42:329. CrossRef

374. CohenMB, NataroJP, BernsteinDI, et al.Prevalence of diarrheagenic Escherichia coli in acute childhood enteritis: a prospective controlled study. J Pediatr2005;146:54. CrossRef

375. MathurR, ReddyV, NaiduAN, et al.Nutritional status and diarrhoeal morbidity: a longitudinal study in rural Indian preschool children. Hum Nutr Clin Nutr1985;39:447.

376. BrownKH. Diarrhea and malnutrition. J Nutr2003;133:328S.

377. BlackRE, BrownKH, BeckerS. Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh. Pediatrics1984;73:799.

378. MataL. Diarrheal disease as a cause of malnutrition. Am J Trop Med Hyg1992;47:16.

379. LevineMM, NalinDR, HooverDL, et al.Immunity to enterotoxigenic Escherichia coli. Infect Immun1979;23:729.

380. SvennerholmAM. From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J Med Res2011;133:188.

381. SvennerholmAM, LundgrenA. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines2012;11:495. CrossRef

382. ZhangW, SackDA. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines2012;11:677. CrossRef

383. PorterCK, RiddleMS, TribbleDR, et al.A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine2011;29:5869. CrossRef

384. HarroC, ChakrabortyS, FellerA, et al.Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol2011;18:1719. CrossRef

385. DupontHL. Traveling internationally: avoiding and treating travelers' diarrhea. Clin Gastroenterol Hepatol2010;8:490; quiz e71. CrossRef

386. SackRB. Prophylactic antimicrobials for traveler's diarrhea: an early history. Clin Infect Dis2005;41(Suppl 8):S553. CrossRef

387. CuthbertAW, HickmanME, MacVinishLJ, et al.Chloride secretion in response to guanylin in colonic epithelial from normal and transgenic cystic fibrosis mice. Br J Pharmacol1994;112:31. CrossRef

388. Bray's discovery of pathogenic Esch. coli as a cause of infantile gastroenteritis. Arch Dis Child1973;48:923. CrossRef

389. RothbaumR, McAdamsAJ, GiannellaR, et al.A clinicopathologic study of enterocyte‐adherent Escherichia coli: a cause of protracted diarrhea in infants. Gastroenterology1982;83:441.

390. MoonHW, WhippSC, ArgenzioRA, et al.Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun1983;41:1340.

391. RothbaumRJ, PartinJC, SaalfieldK, et al.An ultrastructural study of enteropathogenic Escherichia coli infection in human infants. Ultrastruct Pathol1983;4:291. CrossRef

392. SchmidtMA. LEEways: tales of EPEC, ATEC and EHEC. Cell Microbiol2010;12:1544. CrossRef

393. GironJA, HoAS, SchoolnikGK. An inducible bundle‐forming pilus of enteropathogenic Escherichia coli. Science1991;254:710. CrossRef

394. ClearyJ, LaiLC, ShawRK, et al.Enteropathogenic Escherichia coli (EPEC) adhesion to intestinal epithelial cells: role of bundle‐forming pili (BFP), EspA filaments and intimin. Microbiology2004;150:527. CrossRef

395. HolmesA, MuhlenS, RoeAJ, et al.The EspF effector, a bacterial pathogen's Swiss army knife. Infect Immun2010;78:4445. CrossRef

396. GironJA, TorresAG, FreerE, et al.The flagella of enteropathogenic Escherichia coli mediate adherence to epithelial cells. Mol Microbiol2002;44:361. CrossRef

397. NichollsL, GrantTH, Robins‐BrowneRM. Identification of a novel genetic locus that is required for in vitro adhesion of a clinical isolate of enterohaemorrhagic Escherichia coli to epithelial cells. Mol Microbiol2000;35:275. CrossRef

398. HicksS, FrankelG, KaperJB, et al.Role of intimin and bundle‐forming pili in enteropathogenic Escherichia coli adhesion to pediatric intestinal tissue in vitro. Infect Immun1998;66:1570.

399. McDanielTK, JarvisKG, DonnenbergMS, et al.A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci U S A1995;92:1664. CrossRef

400. GarmendiaJ, FrankelG, CrepinVF. Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation. Infect Immun2005;73:2573. CrossRef

401. FrankelG, PhillipsAD. Attaching effacing Escherichia coli and paradigms of Tir‐triggered actin polymerization: getting off the pedestal. Cell Microbiol2008;10:549. CrossRef

402. McNamaraBP, KoutsourisA, O'ConnellCB, et al.Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J Clin Invest2001;107:621. CrossRef

403. DeanP, KennyB. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol Microbiol2004;54:665. CrossRef

404. DeanP, ScottJA, KnoxAA, et al.The enteropathogenic E. coli effector EspF targets and disrupts the nucleolus by a process regulated by mitochondrial dysfunction. PLoS Pathog2010;6:e1000961. CrossRef

405. Ruchaud‐SparaganoMH, MuhlenS, DeanP, et al.The enteropathogenic E. coli (EPEC) Tir effector inhibits NF‐kappaB activity by targeting TNFalpha receptor‐associated factors. PLoS Pathog2011;7:e1002414. CrossRef

406. SharmaR, TesfayS, TomsonFL, et al.Balance of bacterial pro‐ and anti‐inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol2006;290:G685. CrossRef

407. DeanP, MarescaM, SchullerS, et al.Potent diarrheagenic mechanism mediated by the cooperative action of three enteropathogenic Escherichia coli‐injected effector proteins. Proc Natl Acad Sci U S A2006;103:1876. CrossRef

408. HechtG, HodgesK, GillRK, et al.Differential regulation of Na+/H+ exchange isoform activities by enteropathogenic E. coli in human intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol2004;287:G370. CrossRef

409. GillRK, BorthakurA, HodgesK, et al.Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli. J Clin Invest2007;117:428. CrossRef

410. BorthakurA, GillRK, HodgesK, et al.Enteropathogenic Escherichia coli inhibits butyrate uptake in Caco‐2 cells by altering the apical membrane MCT1 level. Am J Physiol Gastrointest Liver Physiol2006;290:G30. CrossRef

411. DeanP, YoungL, QuitardS, et al.Insights into the pathogenesis of enteropathogenic E. coli using an improved intestinal enterocyte model. PLoS ONE2013;8:e55284. CrossRef

412. MelliesJL, ElliottSJ, SperandioV, et al.The Per regulon of enteropathogenic Escherichia coli: identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)‐encoded regulator (Ler). Mol Microbiol1999;33:296. CrossRef

413. GlotfeltyLG, HechtGA. Enteropathogenic E. coli effectors EspG1/G2 disrupt tight junctions: new roles and mechanisms. Ann N Y Acad Sci2012;1258:149. CrossRef

414. DeanP, MuhlenS, QuitardS, et al.The bacterial effectors EspG and EspG2 induce a destructive calpain activity that is kept in check by the co‐delivered Tir effector. Cell Microbiol2010;12:1308. CrossRef

415. TrabulsiLR, KellerR, Tardelli GomesTA. Typical and atypical enteropathogenic Escherichia coli. Emerg Infect Dis2002;8:508. CrossRef

416. VernacchioL, VezinaRM, MitchellAA, et al.Characteristics of persistent diarrhea in a community‐based cohort of young US children. J Pediatr Gastroenterol Nutr2006;43:52. CrossRef

417. NguyenRN, TaylorLS, TauschekM, et al.Atypical enteropathogenic Escherichia coli infection and prolonged diarrhea in children. Emerg Infect Dis2006;12:597. CrossRef

418. WightJP, RhodesP, ChapmanPA, et al.Outbreaks of food poisoning in adults due to Escherichia coli O111 and campylobacter associated with coach trips to northern France. Epidemiol Infect1997;119:9. CrossRef

419. HillSM, PhillipsAD, Walker‐SmithJA. Enteropathogenic Escherichia coli and life threatening chronic diarrhoea. Gut1991;32:154. CrossRef

420. NataroJP, KaperJB, Robins‐BrowneR, et al.Patterns of adherence of diarrheagenic Escherichia coli to HEp‐2 cells. Pediatr Infect Dis J1987;6:829. CrossRef

421. NataroJP, MaherKO, MackieP, et al.Characterization of plasmids encoding the adherence factor of enteropathogenic Escherichia coli. Infect Immun1987;55:2370.

422. OkekeIN, LamikanraA, CzeczulinJ, et al.Heterogeneous virulence of enteroaggregative Escherichia coli strains isolated from children in Southwest Nigeria. J Infect Dis2000;181:252. CrossRef

423. WankeCA, MayerH, WeberR, et al.Enteroaggregative Escherichia coli as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. J Infect Dis1998;178:185. CrossRef

424. HuangDB, NataroJP, DuPontHL, et al.Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta‐analysis. Clin Infect Dis2006;43:556. CrossRef

425. AraujoJM, TabarelliGF, ArandaKR, et al.Typical enteroaggregative and atypical enteropathogenic types of Escherichia coli are the most prevalent diarrhea‐associated pathotypes among Brazilian children. J Clin Microbiol2007;45:3396. CrossRef

426. HuangDB, BrownEL, DuPontHL, et al.Seroprevalence of the enteroaggregative Escherichia coli virulence factor dispersin among USA travellers to Cuernavaca, Mexico: a pilot study. J Med Microbiol2008;57:476. CrossRef

427. BoisenN, StruveC, ScheutzF, et al.New adhesin of enteroaggregative Escherichia coli related to the Afa/Dr/AAF family. Infect Immun2008;76:3281. CrossRef

428. VilaJ, VargasM, HendersonIR, et al.Enteroaggregative escherichia coli virulence factors in traveler's diarrhea strains. J Infect Dis2000;182:1780. CrossRef

429. SavarinoSJ, FasanoA, RobertsonDC, et al.Enteroaggregative Escherichia coli elaborate a heat‐stable enterotoxin demonstrable in an in vitro rabbit intestinal model. J Clin Invest1991;87:1450. CrossRef

430. SavarinoSJ, McVeighA, WatsonJ, et al.Enteroaggregative Escherichia coli heat‐stable enterotoxin is not restricted to enteroaggregative E. coli. J Infect Dis1996;173:1019. CrossRef

431. FasanoA, NoriegaFR, LiaoFM, et al.Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. Gut1997;40:505. CrossRef

432. SavarinoSJ, FasanoA, WatsonJ, et al.Enteroaggregative Escherichia coli heat‐stable enterotoxin 1 represents another subfamily of E. coli heat‐stable toxin. Proc Natl Acad Sci U S A1993;90:3093. CrossRef

433. DuttaPR, CappelloR, Navarro‐GarciaF, et al.Functional comparison of serine protease autotransporters of enterobacteriaceae. Infect Immun2002;70:7105. CrossRef

434. KhanMA, KangJ, SteinerTS. Enteroaggregative Escherichia coli flagellin‐induced interleukin‐8 secretion requires Toll‐like receptor 5‐dependent p38 MAP kinase activation. Immunology2004;112:651. CrossRef

435. HarringtonSM, StraumanMC, AbeCM, et al.Aggregative adherence fimbriae contribute to the inflammatory response of epithelial cells infected with enteroaggregative Escherichia coli. Cell Microbiol2005;7:1565. CrossRef

436. NataroJP. Enteroaggregative Escherichia coli pathogenesis. Curr Opin Gastroenterol2005;21:4.

437. FloresJ, OkhuysenPC. Enteroaggregative Escherichia coli infection. Curr Opin Gastroenterol2009;25:8. CrossRef

438. FrankC, WerberD, CramerJP, et al.Epidemic profile of Shiga‐toxin‐producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med2011;365:1771. CrossRef

439. RaskoDA, WebsterDR, SahlJW, et al.Origins of the E. coli strain causing an outbreak of hemolytic‐uremic syndrome in Germany. N Engl J Med2011;365:709. CrossRef

440. KooHL, JiangZD, BrownE, et al.Coliform contamination of vegetables obtained from popular restaurants in Guadalajara, Mexico, and Houston, Texas. Clin Infect Dis2008;47:218. CrossRef

441. HuangDB, MohamedJA, NataroJP, et al.Virulence characteristics and the molecular epidemiology of enteroaggregative Escherichia coli isolates from travellers to developing countries. J Med Microbiol2007;56:1386. CrossRef

442. ScaviaG, StaffolaniM, FisichellaS, et al.Enteroaggregative Escherichia coli associated with a foodborne outbreak of gastroenteritis. J Med Microbiol2008;57:1141. CrossRef

443. HaradaT, HiroiM, KawamoriF, et al.A food poisoning diarrhea outbreak caused by enteroaggregative Escherichia coli serogroup O126:H27 in Shizuoka, Japan. Jpn J Infect Dis2007;60:154.

444. Wallace‐GadsdenF, JohnsonJR, WainJ, et al.Enteroaggregative Escherichia coli related to uropathogenic clonal group A. Emerg Infect Dis2007;13:757. CrossRef

445. JiangZD, GreenbergD, NataroJP, et al.Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol2002;40:4185. CrossRef

446. OpintanJA, BisharRA, NewmanMJ, et al.Carriage of diarrhoeagenic Escherichia coli by older children and adults in Accra, Ghana. Trans R Soc Trop Med Hyg2010;104:504. CrossRef

447. CennimoD, AbbasA, HuangDB, et al.The prevalence and virulence characteristics of enteroaggregative Escherichia coli at an urgent‐care clinic in the USA: a case‐control study. J Med Microbiol2009;58:403. CrossRef

448. OundoJO, KariukiSM, BogaHI, et al.High incidence of enteroaggregative Escherichia coli among food handlers in three areas of Kenya: a possible transmission route of travelers' diarrhea. J Travel Med2008;15:31. CrossRef

449. HuangDB, MohantyA, DuPontHL, et al.A review of an emerging enteric pathogen: enteroaggregative Escherichia coli. J Med Microbiol2006;55:1303. CrossRef

450. Gassama‐SowA, SowPS, GueyeM, et al.Characterization of pathogenic Escherichia coli in human immunodeficiency virus‐related diarrhea in Senegal. J Infect Dis2004;189:75. CrossRef

451. SteinerTS, LimaAA, NataroJP, et al.Enteroaggregative Escherichia coli produce intestinal inflammation and growth impairment and cause interleukin‐8 release from intestinal epithelial cells. J Infect Dis1998;177:88. CrossRef

452. JiangZD, OkhuysenPC, GuoDC, et al.Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin‐8 promotor region. J Infect Dis2003;188:506. CrossRef

453. GlandtM, AdachiJA, MathewsonJJ, et al.Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Clin Infect Dis1999;29:335. CrossRef

454. WankeCA, GerriorJ, BlaisV, et al.Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. J Infect Dis1998;178:1369. CrossRef

455. YamamotoT, KoyamaY, MatsumotoM, et al.Localized, aggregative, and diffuse adherence to HeLa cells, plastic, and human small intestines by Escherichia coli isolated from patients with diarrhea. J Infect Dis1992;166:1295. CrossRef

456. YamamotoT, EcheverriaP, YokotaT. Drug resistance and adherence to human intestines of enteroaggregative Escherichia coli. J Infect Dis1992;165:744. CrossRef

457. HaiderK, FaruqueSM, ShahidNS, et al.Enteroaggregative Escherichia coli infections in Bangladeshi children: clinical and microbiological features. J Diarrhoeal Dis Res1991;9:318.

458. SangWK, OundoJO, MwituriaJK, et al.Multidrug‐resistant enteroaggregative Escherichia coli associated with persistent diarrhea in Kenyan children. Emerg Infect Dis1997;3:373. CrossRef

459. VilaJ, VargasM, RuizJ, et al.Susceptibility patterns of enteroaggregative Escherichia coli associated with traveller's diarrhoea: emergence of quinolone resistance. J Med Microbiol2001;50:996. CrossRef

460. EricssonCD, DuPontHL, OkhuysenPC, et al.Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med2007;14:312. CrossRef

461. DuPontHL. Therapy for and prevention of traveler's diarrhea. Clin Infect Dis2007;45(Suppl 1):S78. CrossRef

462. OkhuysenPC. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. Curr Opin Infect Dis2005;18:522. CrossRef

463. Ouyang‐LatimerJ, JafriS, VanTasselA, et al.In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother2011;55:874. CrossRef

464. VialPA, MathewsonJJ, DuPontHL, et al.Comparison of two assay methods for patterns of adherence to HEp‐2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol1990;28:882.

465. VidalM, KrugerE, DuranC, et al.Single multiplex PCR assay to identify simultaneously the six categories of diarrheagenic Escherichia coli associated with enteric infections. J Clin Microbiol2005;43:5362. CrossRef

466. SouzaTB, LozerDM, KitagawaSM, et al.Real‐time multiplex PCR assay and melting curve analysis for identifying diarrheagenic Escherichia coli. J Clin Microbiol2013;51:1031. CrossRef

467. NguyenTV, Le VanP, Le HuyC, et al.Detection and characterization of diarrheagenic Escherichia coli from young children in Hanoi, Vietnam. J Clin Microbiol2005;43:755. CrossRef

468. OlesenB, NeimannJ, BottigerB, et al.Etiology of diarrhea in young children in Denmark: a case‐control study. J Clin Microbiol2005;43:3636. CrossRef

469. EwingWH, GravattiJL. Shigella types encountered in the Mediterranean area. J Bacteriol1947;53:191.

470. HobbsBC, ThomasME, TaylorJ. School outbreak of gastro‐enteritis associated with a pathogenic paracolon bacillus. Lancet1949;2:530. CrossRef

471. EwingWH, ReavisRW, DavisBR. Provisional Shigella serotypes. Can J Microbiol1958;4:89. CrossRef

472. LevineMM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis1987;155:377. CrossRef

473. TaylorDN, EcheverriaP, SethabutrO, et al.Clinical and microbiologic features of Shigella and enteroinvasive Escherichia coli infections detected by DNA hybridization. J Clin Microbiol1988;26:1362.

474. CossartP, SansonettiPJ. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science2004;304:242. CrossRef

475. HaleTL, SansonettiPJ, SchadPA, et al.Characterization of virulence plasmids and plasmid‐associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and Escherichia coli. Infect Immun1983;40:340.

476. NiebuhrK, GiuriatoS, PedronT, et al.Conversion of PtdIns(4,5)P(2) into PtdIns(5)P by the S.flexneri effector IpgD reorganizes host cell morphology. EMBO J2002;21:5069. CrossRef

477. SmajsD, WeinstockGM. The iron‐ and temperature‐regulated cjrBC genes of Shigella and enteroinvasive Escherichia coli strains code for colicin Js uptake. J Bacteriol2001;183:3958. CrossRef

478. HarrisJR, MarianoJ, WellsJG, et al.Person‐to‐person transmission in an outbreak of enteroinvasive Escherichia coli. Am J Epidemiol1985;122:245.

479. BilgeSS, ClausenCR, LauW, et al.Molecular characterization of a fimbrial adhesin, F1845, mediating diffuse adherence of diarrhea‐associated Escherichia coli to HEp‐2 cells. J Bacteriol1989;171:4281.

480. JallatC, LivrelliV, Darfeuille‐MichaudA, et al.Escherichia coli strains involved in diarrhea in France: high prevalence and heterogeneity of diffusely adhering strains. J Clin Microbiol1993;31:2031.

481. LevineMM, FerreccioC, PradoV, et al.Epidemiologic studies of Escherichia coli diarrheal infections in a low socioeconomic level peri‐urban community in Santiago, Chile. Am J Epidemiol1993;138:849.

482. ServinAL. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev2005;18:264. CrossRef

483. GoluszkoP, PopovV, SelvaranganR, et al.Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule‐dependent invasion to the HeLa epithelial cell line. J Infect Dis1997;176:158. CrossRef

484. PeifferI, ServinAL, Bernet‐CamardMF. Piracy of decay‐accelerating factor (CD55) signal transduction by the diffusely adhering strain Escherichia coli C1845 promotes cytoskeletal F‐actin rearrangements in cultured human intestinal INT407 cells. Infect Immun1998;66:4036.

485. PeifferI, Bernet‐CamardMF, RoussetM, et al.Impairments in enzyme activity and biosynthesis of brush border‐associated hydrolases in human intestinal Caco‐2/TC7 cells infected by members of the Afa/Dr family of diffusely adhering Escherichia coli. Cell Microbiol2001;3:341. CrossRef

486. PeifferI, Blanc‐PotardAB, Bernet‐CamardMF, et al.Afa/Dr diffusely adhering Escherichia coli C1845 infection promotes selective injuries in the junctional domain of polarized human intestinal Caco‐2/TC7 cells. Infect Immun2000;68:3431. CrossRef

487. ArikawaK, MerazIM, NishikawaY, et al.Interleukin‐8 secretion by epithelial cells infected with diffusely adherent Escherichia coli possessing Afa adhesin‐coding genes. Microbiol Immunol2005;49:493. CrossRef

488. BetisF, BrestP, HofmanV, et al.The Afa/Dr adhesins of diffusely adhering Escherichia coli stimulate interleukin‐8 secretion, activate mitogen‐activated protein kinases, and promote polymorphonuclear transepithelial migration in T84 polarized epithelial cells. Infect Immun2003;71:1068. CrossRef

489. GermaniY, BegaudE, DuvalP, et al.Prevalence of enteropathogenic, enteroaggregative, and diffusely adherent Escherichia coli among isolates from children with diarrhea in new Caledonia. J Infect Dis1996;174:1124. CrossRef

490. OoiST, LorberB. Gastroenteritis due to Listeria monocytogenes. Clin Infect Dis2005;40:1327. CrossRef

491. AboutalebN, KuijperEJ, van DisselJT. Emerging infectious colitis. Curr Opin Gastroenterol2014;30:106. CrossRef

492. CabanesD, DehouxP, DussurgetO, et al.Surface proteins and the pathogenic potential of Listeria monocytogenes. Trends Microbiol2002;10:238. CrossRef

493. MengaudJ, OhayonH, GounonP, et al.E‐cadherin is the receptor for internalin, a surface protein required for entry of L. monocytogenes into epithelial cells. Cell1996;84:923. CrossRef

494. DussurgetO, Pizarro‐CerdaJ, CossartP. Molecular determinants of Listeria monocytogenes virulence. Annu Rev Microbiol2004;58:587. CrossRef

495. CobbCA, CurtisGD, BansiDS, et al.Increased prevalence of Listeria monocytogenes in the faeces of patients receiving long‐term H2‐antagonists. Eur J Gastroenterol Hepatol1996;8:1071. CrossRef

496. HofH. Listeria monocytogenes: a causative agent of gastroenteritis?Eur J Clin Microbiol Infect Dis2001;20:369.

497. GahanCG, HillC. Gastrointestinal phase of Listeria monocytogenes infection. J Appl Microbiol2005;98:1345. CrossRef

498. SleatorRD, WoutersJ, GahanCG, et al.Analysis of the role of OpuC, an osmolyte transport system, in salt tolerance and virulence potential of Listeria monocytogenes. Appl Environ Microbiol2001;67:2692. CrossRef

499. BegleyM, GahanCG, HillC. Bile stress response in Listeria monocytogenes LO28: adaptation, cross‐protection, and identification of genetic loci involved in bile resistance. Appl Environ Microbiol2002;68:6005. CrossRef

500. WamplerJL, KimKP, JaradatZ, et al.Heat shock protein 60 acts as a receptor for the Listeria adhesion protein in Caco‐2 cells. Infect Immun2004;72:931. CrossRef

501. KooOK, AmalaradjouMA, BhuniaAK. Recombinant probiotic expressing Listeria adhesion protein attenuates Listeria monocytogenes virulence in vitro. PLoS ONE2012;7:e29277. CrossRef

502. FarberJM, PeterkinPI. Listeria monocytogenes, a food‐borne pathogen. Microbiol Rev1991;55:476.

503. AllerbergerF, WagnerM. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect2010;16:16. CrossRef

504. MahonyJ, McAuliffeO, RossRP, et al.Bacteriophages as biocontrol agents of food pathogens. Curr Opin Biotechnol2011;22:157. CrossRef

505. SchlechWF3rd, SchlechWF, HaldaneH, et al.Does sporadic Listeria gastroenteritis exist? A 2‐year population‐based survey in Nova Scotia, Canada. Clin Infect Dis2005;41:778. CrossRef

506. AndritsosND, MataragasM, KaraberiV, et al.Performance of three culture media commonly used for detecting Listeria monocytogenes. J Food Prot2012;75:1518. CrossRef

507. LindstedtBA. Genotyping of selected bacterial enteropathogens in Norway. Int J Med Microbiol2011;301:648. CrossRef

508. HofH. An update on the medical management of listeriosis. Expert Opin Pharmacother2004;5:1727. CrossRef

509. CrumNF. Update on Listeria monocytogenes infection. Curr Gastroenterol Rep2002;4:287. CrossRef

510. SmithT. The hog‐cholera group of bacteria. US Bur Anim Ind Bull1894;6.

511. LouisPCA. Recherches Anatomiques, Pathologiques et Therapeutiques sur la Maladie Connue sous les noms de Gastroenterite, Fievre, Putride, Adynamiques, Ataxique, Typoide, Comparee avec les Maladies Aigues les Plus Ordinaires. Paris: J‐B Bailliere; 1829.

512. JennerW. On the Identity or Non‐identity of Typhoid and Typhus Fevers. London: C&J Adlard; 1850.

513. SchroeterJ. Kryptogamenflora von Schleisien Bd. B. Breslau: JU Kern; 1885.

514. PfeifferR, KalleW. Experimentelle untersuchunger zur Frage der Schitzimphung des Menschen geger typhus addominalis. Dtsch Med Wochenschr1896;22.

515. KauffmanF. The diagnosis of Salmonella Types. Springfield, IL: Charles C Thomas; 1950.

516. VoetschAC, Van GilderTJ, AnguloFJ, et al.FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis2004;38(Suppl 3):S127. CrossRef

517. SuLH, ChiuCH, ChuC, et al.Antimicrobial resistance in nontyphoid Salmonella serotypes: a global challenge. Clin Infect Dis2004;39:546. CrossRef

518. HelmsM, EthelbergS, MolbakK. International Salmonella Typhimurium DT104 infections, 1992–2001. Emerg Infect Dis2005;11:859. CrossRef

519. WeinbergerM, KellerN. Recent trends in the epidemiology of non‐typhoid Salmonella and antimicrobial resistance: the Israeli experience and worldwide review. Curr Opin Infect Dis2005;18:513. CrossRef

520. ScallanE, MahonBE, HoekstraRM, et al.Estimates of illnesses, hospitalizations and deaths caused by major bacterial enteric pathogens in young children in the United States. Pediatr Infect Dis J2013;32:217. CrossRef

521. ParryCM, ThrelfallEJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis2008;21:531. CrossRef

522. KennedyM, VillarR, VugiaDJ, et al.Hospitalizations and deaths due to Salmonella infections, FoodNet, 1996–1999. Clin Infect Dis2004;38(Suppl 3):S142. CrossRef

523. SwaminathanB, BarrettTJ, FieldsP. Surveillance for human Salmonella infections in the United States. JAOAC Int2006;89:553.

524. DoorduynY, Van Den BrandhofWE, Van DuynhovenYT, et al.Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non‐DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect2006;134:617. CrossRef

525. MusherDM, MusherBL. Contagious acute gastrointestinal infections. N Engl J Med2004;351:2417. CrossRef

526. FabregaA, VilaJ. Salmonella enterica serovar Typhimurium skills to succeed in the host: virulence and regulation. Clin Microbiol Rev2013;26:308. CrossRef

527. ParkhillJ, DouganG, JamesKD, et al.Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature2001;413:848. CrossRef

528. PatelJC, GalanJE. Manipulation of the host actin cytoskeleton by Salmonella–all in the name of entry. Curr Opin Microbiol2005;8:10. CrossRef

529. Blanc‐PotardAB, GroismanEA. The Salmonella selC locus contains a pathogenicity island mediating intramacrophage survival. EMBO J1997;16:5376. CrossRef

530. WongKK, McClellandM, StillwellLC, et al.Identification and sequence analysis of a 27‐kilobase chromosomal fragment containing a Salmonella pathogenicity island located at 92 minutes on the chromosome map of Salmonella enterica serovar typhimurium LT2. Infect Immun1998;66:3365.

531. KissT, MorganE, NagyG. Contribution of SPI‐4 genes to the virulence of Salmonella enterica. FEMS Microbiol Lett2007;275:153. CrossRef

532. de JongHK, ParryCM, van der PollT, et al.Host‐pathogen interaction in invasive Salmonellosis. PLoS Pathog2012;8:e1002933. CrossRef

533. GewirtzAT, NavasTA, LyonsS, et al.Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol2001;167:1882. CrossRef

534. GewirtzAT, SimonPOJr, SchmittCK, et al.Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response. J Clin Invest2001;107:99. CrossRef

535. McCormickBA, ParkosCA, ColganSP, et al.Apical secretion of a pathogen‐elicited epithelial chemoattractant activity in response to surface colonization of intestinal epithelia by Salmonella typhimurium. J Immunol1998;160:455.

536. MrsnyRJ, GewirtzAT, SiccardiD, et al.Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc Natl Acad Sci U S A2004;101:7421. CrossRef

537. DixonJM. Effect of antibiotic treatment on duration of excretion of Salmonella typhimurium by children. Br Med J1965;2:1343. CrossRef

538. BuchwaldDS, BlaserMJ. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis1984;6:345. CrossRef

539. ThielmanNM, GuerrantRL. Clinical practice. Acute infectious diarrhea. N Engl J Med2004;350:38. CrossRef

540. GordonMA. Salmonella infections in immunocompromised adults. J Infect2008;56:413. CrossRef

541. CrumNF. Non‐typhi Salmonella empyema: case report and review of the literature. Scand J Infect Dis2005;37:852. CrossRef

542. VelgeP, CloeckaertA, BarrowP. Emergence of Salmonella epidemics: the problems related to Salmonella enterica serotype Enteritidis and multiple antibiotic resistance in other major serotypes. Vet Res2005;36:267. CrossRef

543. MeltzerE, SchwartzE. Enteric fever: a travel medicine oriented view. Curr Opin Infect Dis2010;23:432. CrossRef

544. HuangDB, DuPontHL. Problem pathogens: extra‐intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis2005;5:341. CrossRef

545. MerminJH, TownesJM, GerberM, et al.Typhoid fever in the United States, 1985–1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med1998;158:633. CrossRef

546. ConnorBA, SchwartzE. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis2005;5:623. CrossRef

547. O'BrienD, TobinS, BrownGV, et al.Fever in returned travelers: review of hospital admissions for a 3‐year period. Clin Infect Dis2001;33:603. CrossRef

548. LozanoR, NaghaviM, ForemanK, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380:2095. CrossRef

549. AnwarE, GoldbergE, FraserA, et al.Vaccines for preventing typhoid fever. Cochrane Database Syst Rev2014;(1):CD001261.

550. LinFY, HoVA, KhiemHB, et al.The efficacy of a Salmonella typhi Vi conjugate vaccine in two‐to‐five‐year‐old children. N Engl J Med2001;344:1263. CrossRef

551. GuzmanCA, BorsutzkyS, Griot‐WenkM, et al.Vaccines against typhoid fever. Vaccine2006;24:3804. CrossRef

552. LevineMM, FerreccioC, AbregoP, et al.Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine1999;17(Suppl 2):S22. CrossRef

553. LevineMM, FerreccioC, BlackRE, et al.Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis2007;45(Suppl 1):S24. CrossRef

554. DartonTC, BlohmkeCJ, PollardAJ. Typhoid epidemiology, diagnostics and the human challenge model. Curr Opin Gastroenterol2014;30:7. CrossRef

555. Garcia‐del PortilloF, FosterJW, FinlayBB. Role of acid tolerance response genes in Salmonella typhimurium virulence. Infect Immun1993;61:4489.

556. FosterJW. The acid tolerance response of Salmonella typhimurium involves transient synthesis of key acid shock proteins. J Bacteriol1993;175:1981.

557. StuartBM, PullenRL. Typhoid; clinical analysis of 360 cases. Arch Intern Med (Chic)1946;78:629. CrossRef

558. SmitsHL. Limitations of typhoid fever diagnostics and the need for prevention. Expert Rev Mol Diagn2013;13:147. CrossRef

559. ButlerT. Treatment of typhoid fever in the 21st century: promises and shortcomings. Clin Microbiol Infect2011;17:959. CrossRef

560. ParryCM, HienTT, DouganG, et al.Typhoid fever. N Engl J Med2002;347:1770. CrossRef

561. ShigaK. Dysenteriebacillus (Bacillus dysenteriae). Zentralblat Fur Bakteriologie1898;24:817.

562. NiyogiSK. Shigellosis. J Microbiol2005;43:133.

563. Res Judicatae: Emerods, mice and the plague of I Samuel VI. Can Med Assoc J1914;4:639.

564. LevineMM, KotloffKL, BarryEM, et al.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol2007;5:540. CrossRef

565. Shigellosis: disease burden, epidemiology and case management. Wkly Epidemiol Rec2005;80:94.

566. BidawidSP, EdesonJF, IbrahimJ, et al.The role of non‐biting flies in the transmission of enteric pathogens (Salmonella species and Shigella species) in Beirut, Lebanon. Ann Trop Med Parasitol1978;72:117.

567. FaragTH, FaruqueAS, WuY, et al.Housefly population density correlates with shigellosis among children in Mirzapur, Bangladesh: a time series analysis. PLoS Negl Trop Dis2013;7:e2280. CrossRef

568. KotloffKL, WinickoffJP, IvanoffB, et al.Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ1999;77:651.

569. KerneisS, GuerinPJ, von SeidleinL, et al.A look back at an ongoing problem: Shigella dysenteriae type 1 epidemics in refugee settings in Central Africa (1993–1995). PLoS ONE2009;4:e4494. CrossRef

570. KotloffKL, NataroJP, BlackwelderWC, et al.Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case‐control study. Lancet2013;382:209. CrossRef

571. SvenungssonB, LagergrenA, EkwallE, et al.Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1‐year prospective study in a Swedish clinic for infectious diseases. Clin Infect Dis2000;30:770. CrossRef

572. YatesJ. Traveler's diarrhea. Am Fam Physician2005;71:2095.

573. DuPontHL, LevineMM, HornickRB, et al.Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis1989;159:1126. CrossRef

574. PazhaniGP, RamamurthyT, MitraU, et al.Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect2005;133:1089. CrossRef

575. EkdahlK, AnderssonY. The epidemiology of travel‐associated shigellosis–regional risks, seasonality and serogroups. J Infect2005;51:222. CrossRef

576. RiesAA, WellsJG, OlivolaD, et al.Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J Infect Dis1994;169:1035. CrossRef

577. BarryEM, PasettiMF, SzteinMB, et al.Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol2013;10:245. CrossRef

578. PasswellJH, HarlevE, AshkenaziS, et al.Safety and immunogenicity of improved Shigella O‐specific polysaccharide‐protein conjugate vaccines in adults in Israel. Infect Immun2001;69:1351. CrossRef

579. PasswellJH, AshkenaziS, HarlevE, et al.Safety and immunogenicity of Shigella sonnei‐CRM9 and Shigella flexneri type 2a‐rEPAsucc conjugate vaccines in one‐ to four‐year‐old children. Pediatr Infect Dis J2003;22:701. CrossRef

580. AshidaH, OgawaM, KimM, et al.Shigella deploy multiple countermeasures against host innate immune responses. Curr Opin Microbiol2011;14:16. CrossRef

581. GirardinSE, BonecaIG, CarneiroLA, et al.Nod1 detects a unique muropeptide from gram‐negative bacterial peptidoglycan. Science2003;300:1584. CrossRef

582. ParsotC. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett2005;252:11. CrossRef

583. PatonAW, PatonJC. Detection and characterization of Shiga toxigenic Escherichia coli by using multiplex PCR assays for stx1, stx2, eaeA, enterohemorrhagic E. coli hlyA, rfbO111, and rfbO157. J Clin Microbiol1998;36:598.

584. BennishML, KhanWA, BegumM, et al.Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis2006;42:356. CrossRef

585. RoutWR, FormalSB, GiannellaRA, et al.Pathophysiology of Shigella diarrhea in the rhesus monkey: intestinal transport, morphological, and bacteriological studies. Gastroenterology1975;68:270.

586. NataroJP, SeriwatanaJ, FasanoA, et al.Identification and cloning of a novel plasmid‐encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun1995;63:4721.

587. Al‐HasaniK, HendersonIR, SakellarisH, et al.The sigA gene which is borne on the she pathogenicity island of Shigella flexneri 2a encodes an exported cytopathic protease involved in intestinal fluid accumulation. Infect Immun2000;68:2457. CrossRef

588. Al‐HasaniK, Navarro‐GarciaF, HuertaJ, et al.The immunogenic SigA enterotoxin of Shigella flexneri 2a binds to HEp‐2 cells and induces fodrin redistribution in intoxicated epithelial cells. PLoS ONE2009;4:e8223. CrossRef

589. FontaineA, ArondelJ, SansonettiPJ. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox‐ mutant of Shigella dysenteriae 1. Infect Immun1988;56:3099.

590. PradoD, ClearyTG, PickeringLK, et al.The relation between production of cytotoxin and clinical features in shigellosis. J Infect Dis1986;154:149. CrossRef

591. KhanWA, DharU, SalamMA, et al.Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics1999;103:E18. CrossRef

592. ZychlinskyA, PrevostMC, SansonettiPJ. Shigella flexneri induces apoptosis in infected macrophages. Nature1992;358:167. CrossRef

593. ZychlinskyA, FittingC, CavaillonJM, et al.Interleukin 1 is released by murine macrophages during apoptosis induced by Shigella flexneri. J Clin Invest1994;94:1328. CrossRef

594. PerdomoOJ, CavaillonJM, HuerreM, et al.Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis. J Exp Med1994;180:1307. CrossRef

595. PerdomoJJ, GounonP, SansonettiPJ. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by Shigella flexneri. J Clin Invest1994;93:633. CrossRef

596. d'HautevilleH, SansonettiPJ. Phosphorylation of IcsA by cAMP‐dependent protein kinase and its effect on intracellular spread of Shigella flexneri. Mol Microbiol1992;6:833. CrossRef

597. LevineMM, DuPontHL, KhodabandelouM, et al.Long‐term Shigella‐carrier state. N Engl J Med1973;288:1169. CrossRef

598. SimonDG, KaslowRA, RosenbaumJ, et al.Reiter's syndrome following epidemic shigellosis. J Rheumatol1981;8:969.

599. LopezEL, Prado‐JimenezV, O'Ryan‐GallardoM, et al.Shigella and Shiga toxin‐producing Escherichia coli causing bloody diarrhea in Latin America. Infect Dis Clin North Am2000;14:41, viii. CrossRef

600. PrietoE, TrevinoM, RajoMC, et al.Shigella flexneri bacteremia in a middle‐aged immunocompetent woman. Scand J Infect Dis2000;32:578. CrossRef

601. KeatA. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med1983;309:1606. CrossRef

602. FinchM, RodeyG, LawrenceD, et al.Epidemic Reiter's syndrome following an outbreak of shigellosis. Eur J Epidemiol1986;2:26. CrossRef

603. KeatA. Reactive arthritis. Adv Exp Med Biol1999;455:201. CrossRef

604. KhanMA. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am1992;18:1.

605. KosterF, LevinJ, WalkerL, et al.Hemolytic‐uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med1978;298:927. CrossRef

606. SakamotoA, KamoS. Clinical, statistical observations on ekiri and bacillary dysentery; a study of 785 cases. Ann Paediatr1956;186:1.

607. DuPontHL, HornickRB, SnyderMJ, et al.Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis1972;125:12. CrossRef

608. BlackRE, LevineMM, ClementsML, et al.Prevention of shigellosis by a Salmonella typhi‐Shigella sonnei bivalent vaccine. J Infect Dis1987;155:1260. CrossRef

609. GuerrantRL, ShieldsDS, ThorsonSM, et al.Evaluation and diagnosis of acute infectious diarrhea. Am J Med1985;78:91. CrossRef

610. DuPontHL, HornickRB. Adverse effect of lomotil therapy in shigellosis. JAMA1973;226:1525. CrossRef

611. Prince ChristopherRH, DavidKV, JohnSM, et al.Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev2010;(1):CD006784.

612. BhattacharyaSK, SurD. An evaluation of current shigellosis treatment. Expert Opin Pharmacother2003;4:1315. CrossRef

613. NaheedA, KalluriP, TalukderKA, et al.Fluoroquinolone‐resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis2004;4:607. CrossRef

614. BasualdoW, ArboA. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J2003;22:374.

615. KhanWA, SeasC, DharU, et al.Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double‐blind, randomized, controlled trial. Ann Intern Med1997;126:697. CrossRef

616. ErdmanSM, BucknerEE, HindlerJF. Options for treating resistant Shigella species infections in children. J Pediatr Pharmacol Ther2008;13:29.

617. SalamMA, SeasC, KhanWA, et al.Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med1995;123:505. CrossRef

618. BennishML, SalamMA, HaiderR, et al.Therapy for shigellosis. II. Randomized, double‐blind comparison of ciprofloxacin and ampicillin. J Infect Dis1990;162:711. CrossRef

619. NewsomSW. Pioneers in infection control: John Snow, Henry Whitehead, the Broad Street pump, and the beginnings of geographical epidemiology. J Hosp Infect2006;64:210. CrossRef

620. SackDA, SackRB, NairGB, et al.Cholera. Lancet2004;363:223. CrossRef

621. Large epidemic of cholera‐like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh. Lancet1993;342:387. CrossRef

622. SiddiqueAK, ZamanK, BaquiAH, et al.Cholera epidemics in Bangladesh: 1985–1991. J Diarrhoeal Dis Res1992;10:79.

623. GlassRI, BeckerS, HuqMI, et al.Endemic cholera in rural Bangladesh, 1966–1980. Am J Epidemiol1982;116:959.

624. SackRB, SiddiqueAK, LonginiIMJr, et al.A 4‐year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J Infect Dis2003;187:96. CrossRef

625. AlamM, SultanaM, NairGB, et al.Toxigenic Vibrio cholerae in the aquatic environment of Mathbaria, Bangladesh. Appl Environ Microbiol2006;72:2849. CrossRef

626. FaruqueSM, IslamMJ, AhmadQS, et al.Self‐limiting nature of seasonal cholera epidemics: role of host‐mediated amplification of phage. Proc Natl Acad Sci U S A2005;102:6119. CrossRef

627. HolmgrenJ, ClemensJ, SackDA, et al.New cholera vaccines. Vaccine1989;7:94. CrossRef

628. TacketCO, CohenMB, WassermanSS, et al.Randomized, double‐blind, placebo‐controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103‐HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun1999;67:6341.

629. CohenMB, GiannellaRA, BeanJ, et al.Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru‐15, a live attenuated oral cholera vaccine. Infect Immun2002;70:1965. CrossRef

630. HeidelbergJF, EisenJA, NelsonWC, et al.DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature2000;406:477. CrossRef

631. ShogomoriH, FutermanAH. Cholera toxin is found in detergent‐insoluble rafts/domains at the cell surface of hippocampal neurons but is internalized via a raft‐independent mechanism. J Biol Chem2001;276:9182. CrossRef

632. SanchezJ, HolmgrenJ. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol2005;17:388. CrossRef

633. BadizadeganK, WheelerHE, FujinagaY, et al.Trafficking of cholera toxin‐ganglioside GM1 complex into Golgi and induction of toxicity depend on actin cytoskeleton. Am J Physiol Cell Physiol2004;287:C1453. CrossRef

634. MouradFH, O'DonnellLJ, DiasJA, et al.Role of 5‐hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins. Gut1995;37:340. CrossRef

635. TurvillJL, MouradFH, FarthingMJ. Crucial role for 5‐HT in cholera toxin but not Escherichia coli heat‐labile enterotoxin‐intestinal secretion in rats. Gastroenterology1998;115:883. CrossRef

636. KirnTJ, LaffertyMJ, SandoeCM, et al.Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by Vibrio cholerae. Mol Microbiol2000;35:896. CrossRef

637. TrucksisM, GalenJE, MichalskiJ, et al.Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci U S A1993;90:5267. CrossRef

638. TrucksisM, ConnTL, WassermanSS, et al.Vibrio cholerae ACE stimulates Ca(2+)‐dependent Cl(−)/HCO(3)(−) secretion in T84 cells in vitro. Am J Physiol Cell Physiol2000;279:C567.

639. FasanoA, BaudryB, PumplinDW, et al.Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A1991;88:5242. CrossRef

640. FasanoA, FiorentiniC, DonelliG, et al.Zonula occludens toxin modulates tight junctions through protein kinase C‐dependent actin reorganization, in vitro. J Clin Invest1995;96:710. CrossRef

641. FasanoA. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol2012;10:1096. CrossRef

642. NalinDR, CashRA, IslamR, et al.Oral maintenance therapy for cholera in adults. Lancet1968;2:370. CrossRef

643. DugganC, FontaineO, PierceNF, et al.Scientific rationale for a change in the composition of oral rehydration solution. JAMA2004;291:2628. CrossRef

644. KhanWA, BennishML, SeasC, et al.Randomised controlled comparison of single‐dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet1996;348:296. CrossRef

645. SahaD, KarimMM, KhanWA, et al.Single‐dose azithromycin for the treatment of cholera in adults. N Engl J Med2006;354:2452. CrossRef

646. KaushikJS, GuptaP, FaridiMM, et al.Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr2010;47:309. CrossRef

647. JohnstonJM, BeckerSF, McFarlandLM. Gastroenteritis in patients with stool isolates of Vibrio vulnificus. Am J Med1986;80:336. CrossRef

648. MeadPS, SlutskerL, GriffinPM, et al.Food‐related illness and death in the united states reply to dr. hedberg. Emerg Infect Dis1999;5:841. CrossRef

649. McLaughlinJB, DePaolaA, BoppCA, et al.Outbreak of Vibrio parahaemolyticus gastroenteritis associated with Alaskan oysters. N Engl J Med2005;353:1463. CrossRef

650. CoverTL, AberRC. Yersinia enterocolitica. N Engl J Med1989;321:16. CrossRef

651. KoehlerKM, LaskyT, FeinSB, et al.Population‐based incidence of infection with selected bacterial enteric pathogens in children younger than five years of age, 1996–1998. Pediatr Infect Dis J2006;25:129. CrossRef

652. OstroffS. Yersinia as an emerging infection: epidemiologic aspects of Yersiniosis. Contrib Microbiol Immunol1995;13:5.

653. RaySM, AhujaSD, BlakePA, et al.Population‐based surveillance for Yersinia enterocolitica infections in FoodNet sites, 1996–1999: higher risk of disease in infants and minority populations. Clin Infect Dis2004;38(Suppl 3):S181. CrossRef

654. van PeltW, de WitMA, WannetWJ, et al.Laboratory surveillance of bacterial gastroenteric pathogens in The Netherlands, 1991–2001. Epidemiol Infect2003;130:431.

655. NuortiJP, NiskanenT, HallanvuoS, et al.A widespread outbreak of Yersinia pseudotuberculosis O:3 infection from iceberg lettuce. J Infect Dis2004;189:766. CrossRef

656. de WitMA, KoopmansMP, KortbeekLM, et al.Etiology of gastroenteritis in sentinel general practices in the netherlands. Clin Infect Dis2001;33:280. CrossRef

657. OngKL, GouldLH, ChenDL, et al.Changing epidemiology of Yersinia enterocolitica infections: markedly decreased rates in young black children, Foodborne Diseases Active Surveillance Network (FoodNet), 1996–2009. Clin Infect Dis2012;54(Suppl 5):S385. CrossRef

658. AsadishadB, GhoshalS, TufenkjiN. Role of cold climate and freeze‐thaw on the survival, transport, and virulence of Yersinia enterocolitica. Environ Sci Technol2013;47:14169. CrossRef

659. BouzaE, DominguezA, MeseguerM, et al.Yersinia enterocolitica Septicemia. Am J Clin Pathol1980;74:404.

660. RabsonAR, HallettAF, KoornhofHJ. Generalized Yersinia enterocolitica infection. J Infect Dis1975;131:447. CrossRef

661. BliskaJB, CopassMC, FalkowS. The Yersinia pseudotuberculosis adhesin YadA mediates intimate bacterial attachment to and entry into HEp‐2 cells. Infect Immun1993;61:3914.

662. LeongJM, FournierRS, IsbergRR. Identification of the integrin binding domain of the Yersinia pseudotuberculosis invasin protein. EMBO J1990;9:1979.

663. HeesemannJ, SingA, TrulzschK. Yersinia's stratagem: targeting innate and adaptive immune defense. Curr Opin Microbiol2006;9:55. CrossRef

664. PujolC, BliskaJB. Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin Immunol2005;114:216. CrossRef

665. CarnielE. The Yersinia high‐pathogenicity island: an iron‐uptake island. Microbes Infect2001;3:561. CrossRef

666. RakinA, SchneiderL, PodladchikovaO. Hunger for iron: the alternative siderophore iron scavenging systems in highly virulent Yersinia. Front Cell Infect Microbiol2012;2:151. CrossRef

667. BottoneEJ. Yersinia enterocolitica: overview and epidemiologic correlates. Microbes Infect1999;1:323. CrossRef

668. El‐MaraghiNR, MairNS. The histopathology of enteric infection with Yersinia pseudotuberculosis. Am J Clin Pathol1979;71:631.

669. PhamJN, BellSM, LanzaroneJY. Biotype and antibiotic sensitivity of 100 clinical isolates of Yersinia enterocolitica. J Antimicrob Chemother1991;28:13. CrossRef

670. PaiCH, GillisF, TuomanenE, et al.Placebo‐controlled double‐blind evaluation of trimethoprim‐sulfamethoxazole treatment of Yersinia enterocolitica gastroenteritis. J Pediatr1984;104:308. CrossRef

671. Hoogkamp‐KorstanjeJA, Stolk‐EngelaarVM. Yersinia enterocolitica infection in children. Pediatr Infect Dis J1995;14:771. CrossRef

672. VoetschAC, AnguloFJ, Rabatsky‐EhrT, et al.Laboratory practices for stool‐specimen culture for bacterial pathogens, including Escherichia coli O157:H7, in the FoodNet sites, 1995–2000. Clin Infect Dis2004;38(Suppl 3):S190. CrossRef

673. GranforsK, JalkanenS, von EssenR, et al.Yersinia antigens in synovial‐fluid cells from patients with reactive arthritis. N Engl J Med1989;320:216. CrossRef

674. SatoK, OuchiK, TakiM. Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome. Pediatr Infect Dis1983;2:123. CrossRef

675. GraceyM. Gastro‐enteritis in Australian children: studies on the aetiology of acute diarrhoea. Ann Trop Paediatr1988;8:68.

676. JandaJM, AbbottSL. Evolving concepts regarding the genus Aeromonas: an expanding Panorama of species, disease presentations, and unanswered questions. Clin Infect Dis1998;27:332. CrossRef

677. ChuYW, WongCH, TsangGK, et al.Lack of association between presentation of diarrhoeal symptoms and faecal isolation of Aeromonas spp. amongst outpatients in Hong Kong. J Med Microbiol2006;55:349. CrossRef

678. KlontzEH, FaruqueAS, DasSK, et al.Clinical and epidemiologic features of diarrheal disease due to Aeromonas hydrophila and Plesiomonas shigelloides infections compared with those due to Vibrio cholerae Non‐O1 and Vibrio parahaemolyticus in Bangladesh. ISRN Microbiol2012;2012:654819. CrossRef

679. SenderovichY, Ken‐DrorS, VainblatI, et al.A molecular study on the prevalence and virulence potential of Aeromonas spp. recovered from patients suffering from diarrhea in Israel. PLoS ONE2012;7:e30070. CrossRef

680. PfeifferML, DuPontHL, OchoaTJ. The patient presenting with acute dysentery–a systematic review. J Infect2012;64:374. CrossRef

681. BeattyME, AshfordDA, GriffinPM, et al.Gastrointestinal anthrax: review of the literature. Arch Intern Med2003;163:2527. CrossRef

682. HoltyJE, KimRY, BravataDM. Anthrax: a systematic review of atypical presentations. Ann Emerg Med2006;48:200. CrossRef

683. CeuppensS, BoonN, UyttendaeleM. Diversity of Bacillus cereus group strains is reflected in their broad range of pathogenicity and diverse ecological lifestyles. FEMS Microbiol Ecol2013;84:433. CrossRef

684. AgataN, OhtaM, MoriM, et al.A novel dodecadepsipeptide, cereulide, is an emetic toxin of Bacillus cereus. FEMS Microbiol Lett1995;129:17.

685. GranumPE. Bacillus cereus and its toxins. Soc Appl Bacteriol Symp Ser1994;23:61S.

686. BeecherDJ, SchoeniJL, WongAC. Enterotoxic activity of hemolysin BL from Bacillus cereus. Infect Immun1995;63:4423.

687. GranumPE, O'SullivanK, LundT. The sequence of the non‐haemolytic enterotoxin operon from Bacillus cereus. FEMS Microbiol Lett1999;177:225. CrossRef

688. LundT, De BuyserML, GranumPE. A new cytotoxin from Bacillus cereus that may cause necrotic enteritis. Mol Microbiol2000;38:254. CrossRef

689. MahlerH, PasiA, KramerJM, et al.Fulminant liver failure in association with the emetic toxin of Bacillus cereus. N Engl J Med1997;336:1142. CrossRef

690. FinlayWJ, LoganNA, SutherlandAD. Bacillus cereus produces most emetic toxin at lower temperatures. Lett Appl Microbiol2000;31:385. CrossRef

691. FrenckRWJr, ClemensJ. Helicobacter in the developing world. Microbes Infect2003;5:705. CrossRef

692. RothenbacherD, BlaserMJ, BodeG, et al.Inverse relationship between gastric colonization of Helicobacter pylori and diarrheal illnesses in children: results of a population‐based cross‐sectional study. J Infect Dis2000;182:1446. CrossRef

693. Castro‐RodriguezJA, Leon‐BaruaR, PennyM. Helicobacter pylori is not a determinant factor of persistent diarrhoea or malnutrition in Peruvian children. Trans R Soc Trop Med Hyg1999;93:537. CrossRef

694. IsenbargerDW, BodhidattaL, HogeCW, et al.Prospective study of the incidence of diarrheal disease and Helicobacter pylori infection among children in an orphanage in Thailand. Am J Trop Med Hyg1998;59:796.

695. RahmanMM, MahalanabisD, SarkerSA, et al.Helicobacter pylori colonization in infants and young children is not necessarily associated with diarrhoea. J Trop Pediatr1998;44:283. CrossRef

696. KehrtR, BeckerM, BrosickeH, et al.Prevalence of Helicobacter pylori infection in Nicaraguan children with persistent diarrhea, diagnosed by the 13C‐urea breath test. J Pediatr Gastroenterol Nutr1997;25:84. CrossRef

697. SullivanPB, ThomasJE, WightDG, et al.Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition. Arch Dis Child1990;65:189. CrossRef

698. SolnickJV. Clinical significance of Helicobacter species other than Helicobacter pylori. Clin Infect Dis2003;36:349. CrossRef

699. FoleyJE, SolnickJV, LapointeJM, et al.Identification of a novel enteric Helicobacter species in a kitten with severe diarrhea. J Clin Microbiol1998;36:908.

700. FoxJG, ChienCC, DewhirstFE, et al.Helicobacter canadensis sp. nov. isolated from humans with diarrhea as an example of an emerging pathogen. J Clin Microbiol2000;38:2546.

701. AndersenLP. New Helicobacter species in humans. Dig Dis2001;19:112. CrossRef

702. UckayI, GarbinoJ, DietrichPY, et al.Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature. BMC Infect Dis2006;6:86. CrossRef

703. KitamuraT, KawamuraY, OhkusuK, et al.Helicobacter cinaedi cellulitis and bacteremia in immunocompetent hosts after orthopedic surgery. J Clin Microbiol2007;45:31. CrossRef

704. BhatP, ShanthakumariS, RajanD. The characterization and significance of Plesiomonas shigelloides and Aeromonas hydrophila isolated from an epidemic of diarrhoea. Indian J Med Res1974;62:1051.

705. HolmbergSD, WachsmuthIK, Hickman‐BrennerFW, et al.Plesiomonas enteric infections in the United States. Ann Intern Med1986;105:690. CrossRef

706. HolmbergSD. Vibrios and Aeromonas. Infect Dis Clin North Am1988;2:655.

707. PinchukIV, BeswickEJ, ReyesVE. Staphylococcal enterotoxins. Toxins (Basel)2010;2:2177. CrossRef

708. NovickRP, SchlievertP, RuzinA. Pathogenicity and resistance islands of staphylococci. Microbes Infect2001;3:585. CrossRef

709. ReisingerEC, FritzscheC, KrauseR, et al.Diarrhea caused by primarily non‐gastrointestinal infections. Nat Clin Pract Gastroenterol Hepatol2005;2:216. CrossRef

710. ChiangMC, JaingTH, WuCT, et al.Streptococcal toxic shock syndrome in children without skin and soft tissue infection: report of four cases. Acta Paediatr2005;94:763. CrossRef

711. SopenaN, Sabria‐LealM, Pedro‐BotetML, et al.Comparative study of the clinical presentation of Legionella pneumonia and other community‐acquired pneumonias. Chest1998;113:1195. CrossRef

712. KirbyBD, SnyderKM, MeyerRD, et al.Legionnaires' disease: report of sixty‐five nosocomially acquired cases of review of the literature. Medicine1980;59:188. CrossRef

713. CallSA, HeudebertG, SaagM, et al.The changing etiology of chronic diarrhea in HIV‐infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol2000;95:3142. CrossRef

714. AnastasiJK, CapiliB. HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control2000;28:262. CrossRef

715. PancharoenC, MekmullicaJ, ThisyakornU. Primary dengue infection: what are the clinical distinctions from secondary infection?Southeast Asian J Trop Med Public Health2001;32:476.

716. WangYH, HuangYC, ChangLY, et al.Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect2003;36:111.

717. TranTH, NguyenTL, NguyenTD, et al.Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med2004;350:1179. CrossRef

718. ChapmanLE, EllisBA, KosterFT, et al.Discriminators between hantavirus‐infected and ‐uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis2002;34:293. CrossRef

719. LeungWK, ToKF, ChanPK, et al.Enteric involvement of severe acute respiratory syndrome‐associated coronavirus infection. Gastroenterology2003;125:1011. CrossRef

720. NdambiR, AkamitunaP, BonnetMJ, et al.Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. J Infect Dis1999;179(Suppl 1):S8. CrossRef

721. Fernández‐GuerreroML, RenedoGSevere diarrhea in pneumococcal bacteremia. JAMA1987;257:1897.

722. HusseinA, NaschitzY, YeshurunD. [Fulminant meningococcemia presenting as a gastroenteritis‐like syndrome]. Harefuah1999;137:371, 431.

723. EnwereG, BineyE, CheungYB, et al.Epidemiologic and clinical characteristics of community‐acquired invasive bacterial infections in children aged 2–29 months in The Gambia. Pediatr Infect Dis J2006;25:700. CrossRef

724. RibeiroAM, MoreiraJL. [Sepsis in childhood: epidemiological profile and microbiologic diagnosis]. J Pediatr (Rio J)1999;75:39. CrossRef

725. Centers for Disease Control and Prevention (CDC). Outbreak of acute febrile illness among athletes participating in triathlons–Wisconsin and Illinois, 1998. MMWR Morb Mortal Wkly Rep1998;47:585.

726. HullHF, MontesJM, MannJM. Plague masquerading as gastrointestinal illness. West J Med1986;145:485.

727. BwakaMA, BonnetMJ, CalainP, et al.Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis1999;179(Suppl 1):S1. CrossRef

728. ZaidiSA, SingerC. Gastrointestinal and hepatic manifestations of tickborne diseases in the United States. Clin Infect Dis2002;34:1206. CrossRef

729. DienstFTJr. Tularemia: a perusal of three hundred thirty‐nine cases. J la State Med Soc1963;115:114.

730. PrasadRN, VirkKJ. Malaria as a cause of diarrhoea–a review. P N G Med J1993;36:337.

731. KrauseR, SchwabE, BachhieslD, et al.Role of Candida in antibiotic‐associated diarrhea. J Infect Dis2001;184:1065. CrossRef

732. HogenauerC, HammerHF, KrejsGJ, et al.Mechanisms and management of antibiotic‐associated diarrhea. Clin Infect Dis1998;27:702. CrossRef

733. McFarlandLV. Antibiotic‐associated diarrhea: epidemiology, trends and treatment. Future Microbiol2008;3:563. CrossRef

734. BoyceJM, HavillNL. Nosocomial antibiotic‐associated diarrhea associated with enterotoxin‐producing strains of methicillin‐resistant Staphylococcus aureus. Am J Gastroenterol2005;100:1828. CrossRef

735. BeaugerieL, PetitJC. Microbial‐gut interactions in health and disease. Antibiotic‐associated diarrhoea. Best Pract Res Clin Gastroenterol2004;18:337. CrossRef

736. OsterholmMT, MacDonaldKL, WhiteKE, et al.An outbreak of a newly recognized chronic diarrhea syndrome associated with raw milk consumption. JAMA1986;256:484. CrossRef

737. KimuraAC, MeadP, WalshB, et al.A large outbreak of Brainerd diarrhea associated with a restaurant in the Red River Valley, Texas. Clin Infect Dis2006;43:55. CrossRef

738. VugiaDJ, AbbottS, MintzED, et al.A restaurant‐associated outbreak of Brainerd diarrhea in California. Clin Infect Dis2006;43:62. CrossRef

739. de BoissieuD, ChaussainM, BadoualJ, et al.Small‐bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr1996;128:203. CrossRef

740. SachdevAH, PimentelM. Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep2012;14:439. CrossRef

741. PimentelM, ChowEJ, LinHC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol2000;95:3503. CrossRef

742. PimentelM, LemboA, CheyWD, et al.Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med2011;364:22. CrossRef

743. KapikianAZ, WyattRG, DolinR, et al.Visualization by immune electron microscopy of a 27‐nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol1972;10:1075.

744. BishopRF, DavidsonGP, HolmesIH, et al.Virus particles in epithelial cells of duodenal mucosa from children with acute non‐bacterial gastroenteritis. Lancet1973;2:1281. CrossRef

745. ShepherdRW, TruslowS, Walker‐SmithJA, et al.Infantile gastroenteritis: a clinical study of reovirus‐like agent infection. Lancet1975;2:1082. CrossRef

746. FlewettTH, BrydenAS, DaviesH. Letter: virus particles in gastroenteritis. Lancet1973;2:1497. CrossRef

747. KapikianAZ, KimHW, WyattRG, et al.Reoviruslike agent in stools: association with infantile diarrhea and development of serologic tests. Science1974;185:1049. CrossRef

748. RoyP. Orbiviruses. In: KnipeDM, HowleyPM(eds). Fields Virology, 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2001: 1835.

749. GriffinDD, KirkwoodCD, ParasharUD, et al.Surveillance of rotavirus strains in the United States: identification of unusual strains. The National Rotavirus Strain Surveillance System collaborating laboratories. J Clin Microbiol2000;38:2784.

750. GentschJR, WoodsPA, RamachandranM, et al.Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis1996;174(Suppl 1):S30. CrossRef

751. SantosN, HoshinoY. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol2005;15:29. CrossRef

752. O'RyanM. The ever‐changing landscape of rotavirus serotypes. Pediatr Infect Dis J2009;28(3 Suppl):S60. CrossRef

753. ClarkHF, LawleyDA, SchafferA, et al.Assessment of the epidemic potential of a new strain of rotavirus associated with the novel G9 serotype which caused an outbreak in the United States for the first time in the 1995–1996 season. J Clin Microbiol2004;42:1434. CrossRef

754. MilesMG, LewisKD, KangG, et al.A systematic review of rotavirus strain diversity in India, Bangladesh, and Pakistan. Vaccine2012;30(Suppl 1):A131. CrossRef

755. ParasharUD, GibsonCJ, BreseeJS, et al.Rotavirus and severe childhood diarrhea. Emerg Infect Dis2006;12:304. CrossRef

756. Rotavirus vaccines WHO position paper: January 2013 – Recommendations. Vaccine2013;31:6170. CrossRef

757. MalekMA, CurnsAT, HolmanRC, et al.Diarrhea‐ and rotavirus‐associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics2006;117:1887. CrossRef

758. DennehyPH, CorteseMM, BegueRE, et al.A case‐control study to determine risk factors for hospitalization for rotavirus gastroenteritis in U.S. children. Pediatr Infect Dis J2006;25:1123. CrossRef

759. GlassRI, ParasharUD, BreseeJS, et al.Rotavirus vaccines: current prospects and future challenges. Lancet2006;368:323. CrossRef

760. FeeneySA, MitchellSJ, MitchellF, et al.Association of the G4 rotavirus genotype with gastroenteritis in adults. J Med Virol2006;78:1119. CrossRef

761. MarshallJ, BotesJ, GorrieG, et al.Rotavirus detection and characterisation in outbreaks of gastroenteritis in aged‐care facilities. J Clin Virol2003;28:331. CrossRef

762. GladstoneBP, RamaniS, MukhopadhyaI, et al.Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med2011;365:337. CrossRef

763. WangFT, MastTC, GlassRJ, et al.Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics2010;125:e208. CrossRef

764. MurphyTV, GargiulloPM, MassoudiMS, et al.Intussusception among infants given an oral rotavirus vaccine. N Engl J Med2001;344:564. CrossRef

765. WeintraubES, BaggsJ, DuffyJ, et al.Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med2014;370:513. CrossRef

766. Ruiz‐PalaciosGM, Perez‐SchaelI, VelazquezFR, et al.Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med2006;354:11. CrossRef

767. VesikariT, MatsonDO, DennehyP, et al.Safety and efficacy of a pentavalent human‐bovine (WC3) reassortant rotavirus vaccine. N Engl J Med2006;354:23. CrossRef

768. CorteseMM, ParasharUD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2009;58(RR‐2):1.

769. GastanaduyPA, Sanchez‐UribeE, Esparza‐AguilarM, et al.Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics2013;131:e1115. CrossRef

770. GreenbergHB, EstesMK. Rotaviruses: from pathogenesis to vaccination. Gastroenterology2009;136:1939. CrossRef

771. CiarletM, EstesMK. Interactions between rotavirus and gastrointestinal cells. Curr Opin Microbiol2001;4:435. CrossRef

772. BallJM, TianP, ZengCQ, et al.Age‐dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science1996;272:101. CrossRef

773. MorrisAP, EstesMK. Microbes and microbial toxins: paradigms for microbial‐mucosal interactions. VIII. Pathological consequences of rotavirus infection and its enterotoxin. Am J Physiol Gastrointest Liver Physiol2001;281:G303.

774. BallJM, MitchellDM, GibbonsTF, et al.Rotavirus NSP4: a multifunctional viral enterotoxin. Viral Immunol2005;18:27. CrossRef

775. DickmanKG, HempsonSJ, AndersonJ, et al.Rotavirus alters paracellular permeability and energy metabolism in Caco‐2 cells. Am J Physiol Gastrointest Liver Physiol2000;279:G757.

776. LundgrenO, PeregrinAT, PerssonK, et al.Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science2000;287:491. CrossRef

777. JourdanN, BrunetJP, SapinC, et al.Rotavirus infection reduces sucrase‐isomaltase expression in human intestinal epithelial cells by perturbing protein targeting and organization of microvillar cytoskeleton. J Virol1998;72:7228.

778. OsborneMP, HaddonSJ, WortonKJ, et al.Rotavirus‐induced changes in the microcirculation of intestinal villi of neonatal mice in relation to the induction and persistence of diarrhea. J Pediatr Gastroenterol Nutr1991;12:111. CrossRef

779. RodriguezWJ, KimHW, ArrobioJO, et al.Clinical features of acute gastroenteritis associated with human reovirus‐like agent in infants and young children. J Pediatr1977;91:188. CrossRef

780. KovacsA, ChanL, HotrakityaC, et al.Serum transaminase elevations in infants with rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr1986;5:873. CrossRef

781. CharlesMD, HolmanRC, CurnsAT, et al.Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993–2002. Pediatr Infect Dis J2006;25:489. CrossRef

782. KnisleyCV, Bednarz‐PrashadAJ, PickeringLK. Detection of rotavirus in stool specimens with monoclonal and polyclonal antibody‐based assay systems. J Clin Microbiol1986;23:897.

783. RaboniSM, NogueiraMB, HakimVM, et al.Comparison of latex agglutination with enzyme immunoassay for detection of rotavirus in fecal specimens. Am J Clin Pathol2002;117:392. CrossRef

784. SiahSP, MerifJ, KaurK, et al.Improved detection of gastrointestinal pathogens using generalised sample processing and amplification panels. Pathology2014;46:53. CrossRef

785. AlamS, AfzalK, MaheshwariM, et al.Controlled trial of hypo‐osmalar versus World Health Organization oral rehydration solution. Indian Pediatr2000;37:952.

786. SarkerSA, CasswallTH, MahalanabisD, et al.Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr Infect Dis J1998;17:1149. CrossRef

787. GuarinoA, CananiRB, RussoS, et al.Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics1994;93:12.

788. GuandaliniS, PensabeneL, ZikriMA, et al.Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr2000;30:54. CrossRef

789. Costa‐RibeiroH, RibeiroTC, MattosAP, et al.Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr2003;36:112. CrossRef

790. Practice parameter: the management of acute gastroenteritis in young children. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Pediatrics1996;97:424.

791. LosonskyGA, JohnsonJP, WinkelsteinJA, et al.Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest1985;76:2362. CrossRef

792. AdlerJL, ZicklR. Winter vomiting disease. J Infect Dis1969;119:668. CrossRef

793. AgusSG, DolinR, WyattRG, et al.Acute infectious nonbacterial gastroenteritis: intestinal histopathology. Histologic and enzymatic alterations during illness produced by the Norwalk agent in man. Ann Intern Med1973;79:18. CrossRef

794. FankhauserRL, NoelJS, MonroeSS, et al.Molecular epidemiology of “Norwalk‐like viruses” in outbreaks of gastroenteritis in the United States. J Infect Dis1998;178:1571. CrossRef

795. ChhabraP, PayneDC, SzilagyiPG, et al.Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008–2009. J Infect Dis2013;208:790. CrossRef

796. LopmanBA, HallAJ, CurnsAT, et al.Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996–2007. Clin Infect Dis2011;52:466. CrossRef

797. BonF, Ambert‐BalayK, GiraudonH, et al.Molecular epidemiology of caliciviruses detected in sporadic and outbreak cases of gastroenteritis in France from December 1998 to February 2004. J Clin Microbiol2005;43:4659. CrossRef

798. WiddowsonMA, SulkaA, BulensSN, et al.Norovirus and foodborne disease, United States, 1991–2000. Emerg Infect Dis2005;11:95. CrossRef

799. KaplanJE, GaryGW, BaronRC, et al.Epidemiology of Norwalk gastroenteritis and the role of Norwalk virus in outbreaks of acute nonbacterial gastroenteritis. Ann Intern Med1982;96:756. CrossRef

800. TurciosRM, WiddowsonMA, SulkaAC, et al.Reevaluation of epidemiological criteria for identifying outbreaks of acute gastroenteritis due to norovirus: United States, 1998–2000. Clin Infect Dis2006;42:964. CrossRef

801. TacketCO, MasonHS, LosonskyG, et al.Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis2000;182:302. CrossRef

802. AtmarRL, BernsteinDI, HarroCD, et al.Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med2011;365:2178. CrossRef

803. WobusCE, ThackrayLB, VirginHW. Murine norovirus: a model system to study norovirus biology and pathogenesis. J Virol2006;80:5104. CrossRef

804. FrenckR, BernsteinDI, XiaM, et al.Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis2012;206:1386. CrossRef

805. HuangP, FarkasT, MarionneauS, et al.Noroviruses bind to human ABO, Lewis, and secretor histo‐blood group antigens: identification of 4 distinct strain‐specific patterns. J Infect Dis2003;188:19. CrossRef

806. BokK, GreenKY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med2012;367:2126. CrossRef

807. KnightA, LiD, UyttendaeleM, et al.A critical review of methods for detecting human noroviruses and predicting their infectivity. Crit Rev Microbiol2013;39:295. CrossRef

808. Danziger‐IsakovL. Gastrointestinal infections after transplantation. Curr Opin Gastroenterol2014;30:40. CrossRef

809. GardnerPS, McGregorCB, DickK. Association between diarrhoea and adenovirus type 7. Br Med J1960;1:91. CrossRef

810. de JongJC, WigandR, KiddAH, et al.Candidate adenoviruses 40 and 41: fastidious adenoviruses from human infant stool. J Med Virol1983;11:215. CrossRef

811. UhnooI, SvenssonL. Clinical and epidemiological features of acute infantile gastroenteritis associated with human rotavirus subgroups 1 and 2. J Clin Microbiol1986;23:551.

812. SchleuningM, Buxbaum‐ConradiH, JagerG, et al.Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J2004;5:135. CrossRef

813. YusufU, HaleGA, CarrJ, et al.Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation2006;81:1398. CrossRef

814. LegrandF, BerrebiD, HouhouN, et al.Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant2001;27:621. CrossRef

815. MadeleyCR, CosgroveBP. Letter: 28 nm particles in faeces in infantile gastroenteritis. Lancet1975;2:451. CrossRef

816. AppletonH, HigginsPG. Letter: viruses and gastroenteritis in infants. Lancet1975;1:1297. CrossRef

817. De BenedictisP, Schultz‐CherryS, BurnhamA, et al.Astrovirus infections in humans and animals – molecular biology, genetic diversity, and interspecies transmissions. Infect Genet Evol2011;11:1529. CrossRef

818. PalomboEA, BishopRF. Annual incidence, serotype distribution, and genetic diversity of human astrovirus isolates from hospitalized children in Melbourne, Australia. J Clin Microbiol1996;34:1750.

819. DennehyPH, NelsonSM, SpangenbergerS, et al.A prospective case‐control study of the role of astrovirus in acute diarrhea among hospitalized young children. J Infect Dis2001;184:10. CrossRef

820. Rodriguez‐BaezN, O'BrienR, QiuSQ, et al.Astrovirus, adenovirus, and rotavirus in hospitalized children: prevalence and association with gastroenteritis. J Pediatr Gastroenterol Nutr2002;35:64. CrossRef

821. LewisDC, LightfootNF, CubittWD, et al.Outbreaks of astrovirus type 1 and rotavirus gastroenteritis in a geriatric in‐patient population. J Hosp Infect1989;14:9. CrossRef

822. GrayJJ, WreghittTG, CubittWD, et al.An outbreak of gastroenteritis in a home for the elderly associated with astrovirus type 1 and human calicivirus. J Med Virol1987;23:377. CrossRef

823. LeeTW, KurtzJB. Prevalence of human astrovirus serotypes in the Oxford region 1976–92, with evidence for two new serotypes. Epidemiol Infect1994;112:187. CrossRef

824. BelliotG, LaveranH, MonroeSS. Outbreak of gastroenteritis in military recruits associated with serotype 3 astrovirus infection. J Med Virol1997;51:101. CrossRef

825. GlassRI, NoelJ, MitchellD, et al.The changing epidemiology of astrovirus‐associated gastroenteritis: a review. Arch Virol Suppl1996;12:287. CrossRef

826. SnodgrassDR, AngusKW, GrayEW, et al.Pathogenesis of diarrhoea caused by astrovirus infections in lambs. Arch Virol1979;60:217. CrossRef

827. DonelliG, SupertiF, TinariA, et al.Mechanism of astrovirus entry into Graham 293 cells. J Med Virol1992;38:271. CrossRef

828. LeeRM, LesslerJ, LeeRA, et al.Incubation periods of viral gastroenteritis: a systematic review. BMC Infect Dis2013;13:446. CrossRef

829. EspulC, MartinezN, NoelJS, et al.Prevalence and characterization of astroviruses in Argentinean children with acute gastroenteritis. J Med Virol2004;72:75. CrossRef

830. LeBaronCW, FurutanNP, LewJF, et al.Viral agents of gastroenteritis. Public health importance and outbreak management. MMWR Recomm Rep1990;39(RR‐5):1.

831. PangXL, VesikariT. Human astrovirus‐associated gastroenteritis in children under 2 years of age followed prospectively during a rotavirus vaccine trial. Acta Paediatr1999;88:532. CrossRef

832. PanchalingamS, AntonioM, HossainA, et al.Diagnostic microbiologic methods in the GEMS‐1 case/control study. Clin Infect Dis2012;55(Suppl 4):S294. CrossRef

833. BjorkholmM, CelsingF, RunarssonG, et al.Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenstrom's macroglobulinemia. Int J Hematol1995;62:117. CrossRef

834. YuenKY, WooPC, LiangRH, et al.Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis1998;30:75. CrossRef

835. GreensonJK, BelitsosPC, YardleyJH, et al.AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann Intern Med1991;114:366. CrossRef

836. GreenbergBL, SackRB, Salazar‐LindoE, et al.Measles‐associated diarrhea in hospitalized children in Lima, Peru: pathogenic agents and impact on growth. J Infect Dis1991;163:495. CrossRef

837. VaravithyaW, AswasuwanaS, PhuapraditP, et al.Etiology of diarrhea in measles. J Med Assoc Thai1989;72(Suppl 1):151.

838. GiordanoMO, MartinezLC, RinaldiD, et al.Detection of picobirnavirus in HIV‐infected patients with diarrhea in Argentina. J Acquir Immune Defic Syndr Hum Retrovirol1998;18:380. CrossRef

839. JamiesonFB, WangEE, BainC, et al.Human torovirus: a new nosocomial gastrointestinal pathogen. J Infect Dis1998;178:1263. CrossRef

840. YamashitaT, SakaeK, KobayashiS, et al.Isolation of cytopathic small round virus (Aichi virus) from Pakistani children and Japanese travelers from Southeast Asia. Microbiol Immunol1995;39:433. CrossRef

841. FanCK, YiehKM, PengMY, et al.Clinical and laboratory features in the early stage of severe acute respiratory syndrome. J Microbiol Immunol Infect2006;39:45.

842. SrikantiahP, CharlesMD, ReaganS, et al.SARS clinical features, United States, 2003. Emerg Infect Dis2005;11:135. CrossRef

843. IsbisterGK, KiernanMC. Neurotoxic marine poisoning. Lancet Neurol2005;4:219. CrossRef

844. SobelJ, PainterJ. Illnesses caused by marine toxins. Clin Infect Dis2005;41:1290. CrossRef

845. JohnsonR, JongEC. Ciguatera: Caribbean and Indo‐Pacific fish poisoning. West J Med1983;138:872.

846. FasanoA, HokamaY, RussellR, et al.Diarrhea in ciguatera fish poisoning: preliminary evaluation of pathophysiological mechanisms. Gastroenterology1991;100:471.

847. GillespieNC, LewisRJ, PearnJH, et al.Ciguatera in Australia. Occurrence, clinical features, pathophysiology and management. Med J Aust1986;145:584.

848. BerlinRM, KingSL, BlytheDG. Symptomatic improvement of chronic fatigue with fluoxetine in ciguatera fish poisoning. Med J Aust1992;157:567.

849. SchnorfH, TaurariiM, CundyT. Ciguatera fish poisoning: a double‐blind randomized trial of mannitol therapy. Neurology2002;58:873. CrossRef

850. CusickKD, SaylerGS. An overview on the marine neurotoxin, saxitoxin: genetics, molecular targets, methods of detection and ecological functions. Mar Drugs2013;11:991. CrossRef

851. NicolasJ, HendriksenPJ, GerssenA, et al.Marine neurotoxins: state of the art, bottlenecks, and perspectives for mode of action based methods of detection in seafood. Mol Nutr Food Res2014;58:87. CrossRef

852. BadenDG, BourdelaisAJ, JacocksH, et al.Natural and derivative brevetoxins: historical background, multiplicity, and effects. Environ Health Perspect2005;113:621. CrossRef

853. KirkpatrickB, FlemingLE, SquicciariniD, et al.Literature review of Florida red tide: implications for human health effects. Harmful Algae2004;3:99. CrossRef

854. PerlTM, BedardL, KosatskyT, et al.An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med1990;322:1775. CrossRef

855. TeitelbaumJS, ZatorreRJ, CarpenterS, et al.Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med1990;322:1781. CrossRef

856. KiernanMC, IsbisterGK, LinCS, et al.Acute tetrodotoxin‐induced neurotoxicity after ingestion of puffer fish. Ann Neurol2005;57:339. CrossRef

857. IsbisterGK, SonJ, WangF, et al.Puffer fish poisoning: a potentially life‐threatening condition. Med J Aust2002;177:650.

858. Centers for Disease Control and Prevention (CDC). Tetrodotoxin poisoning associated with eating puffer fish transported from Japan–California, 1996. MMWR Morb Mortal Wkly Rep1996;45:389.

859. CiminielloP, FattorussoE. Bivalve molluscs as vectors of marine biotoxins involved in seafood poisoning. Prog Mol Subcell Biol2006;43:53. CrossRef

860. HunterT. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell1995;80:225. CrossRef

861. TubaroA, Dell'ovoV, SosaS, et al.Yessotoxins: a toxicological overview. Toxicon2010;56:163. CrossRef

862. OnumaY, SatakeM, UkenaT, et al.Identification of putative palytoxin as the cause of clupeotoxism. Toxicon1999;37:55. CrossRef

863. MorrowJD, MargoliesGR, RowlandJ, et al.Evidence that histamine is the causative toxin of scombroid‐fish poisoning. N Engl J Med1991;324:716. CrossRef

864. VickersJ, SafaiB. Images in clinical medicine. Scombroid poisoning. N Engl J Med2013;368:e31. CrossRef

865. PerkinsRA, MorganSS. Poisoning, envenomation, and trauma from marine creatures. Am Fam Physician2004;69:885.

866. PetersRP, VerweijSP, NijstenN, et al.Evaluation of sexual history‐based screening of anatomic sites for chlamydia trachomatis and neisseria gonorrhoeae infection in men having sex with men in routine practice. BMC Infect Dis2011;11:203. CrossRef

867. QuinnTC, StammWE, GoodellSE, et al.The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med1983;309:576. CrossRef

868. BissessorM, FairleyCK, ReadT, et al.The etiology of infectious proctitis in men who have sex with men differs according to HIV status. Sex Transm Dis2013;40:768. CrossRef

869. QuinnTC, GoodellSE, MkrtichianE, et al.Chlamydia trachomatis proctitis. N Engl J Med1981;305:195. CrossRef

870. HoieS, KnudsenLS, GerstoftJ. Lymphogranuloma venereum proctitis: a differential diagnose to inflammatory bowel disease. Scand J Gastroenterol2011;46:503. CrossRef

871. RompaloAM, SuchlandRJ, PriceCB, et al.Rapid diagnosis of Chlamydia trachomatis rectal infection by direct immunofluorescence staining. J Infect Dis1987;155:1075. CrossRef

872. Centers for Disease Control and Prevention (CDC). WorkowskiKA, BermanSM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep2006;55(RR‐11):1.

873. KleinEJ, FisherLS, ChowAW, et al.Anorectal gonococcal infection. Ann Intern Med1977;86:340. CrossRef

874. Centers for Disease Control and Prevention (CDC). Increases in fluoroquinolone‐resistant Neisseria gonorrhoeae among men who have sex with men–United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep2004;53:335.

875. MindelA, ToveySJ, TimminsDJ, et al.Primary and secondary syphilis, 20 years' experience. 2. Clinical features. Genitourin Med1989;65:1.

876. HutchinsonCM, HookEW3rd.Syphilis in adults. Med Clin North Am1990;74:1389.

877. SurawiczCM, RobertsPL, RompaloA, et al.Intestinal spirochetosis in homosexual men. Am J Med1987;82:587. CrossRef

878. HofstetterAM, RosenthalSL, StanberryLR. Current thinking on genital herpes. Curr Opin Infect Dis2014;27:75. CrossRef

879. SurawiczCM, GoodellSE, QuinnTC, et al.Spectrum of rectal biopsy abnormalities in homosexual men with intestinal symptoms. Gastroenterology1986;91:651.

880. KoutskyLA, StevensCE, HolmesKK, et al.Underdiagnosis of genital herpes by current clinical and viral‐isolation procedures. N Engl J Med1992;326:1533. CrossRef

881. ConeRW, HobsonAC, PalmerJ, et al.Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. J Infect Dis1991;164:757. CrossRef

882. BelsheRB, LeonePA, BernsteinDI, et al.Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med2012;366:34. CrossRef

883. ScholefieldJH, SonnexC, TalbotIC, et al.Anal and cervical intraepithelial neoplasia: possible parallel. Lancet1989;2:765. CrossRef

884. BashiSA. Cryotherapy versus podophyllin in the treatment of genital warts. Int J Dermatol1985;24:535. CrossRef

885. SimmonsPD. Podophyllin 10% and 25% in the treatment of ano‐genital warts. A comparative double‐blind study. Br J Vener Dis1981;57:208.

886. SimmonsPD, LangletF, ThinRN. Cryotherapy versus electrocautery in the treatment of genital warts. Br J Vener Dis1981;57:273.

887. JensenSL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet1985;2:1146. CrossRef

888. VenderR, BourcierM, BhatiaN, et al.Therapeutic options for external genital warts. J Cutan Med Surg2013;17(Suppl 2):S61. CrossRef

889. MarkowitzLE, DunneEF, SaraiyaM, et al.Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2007;56(RR‐2):1.

890. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep2011;60:1705.

891. HolmanDM, BenardV, RolandKB, et al.Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr2014;168:76. CrossRef

892. MayhewA, MullinsTL, DingL, et al.Risk perceptions and subsequent sexual behaviors after HPV vaccination in adolescents. Pediatrics2014;133:404. CrossRef

893. GreenwoodD, SlackR, PeuthererJ. Medical Microbiology, 15th edn. Edinburgh: Churchill Livingstone; 1997.

894. HavensPL, HoffmanGM, ShithKJ. The homogeneous nature of the hemolytic uremic syndrome. Clin Pediatr (Phila)1989;28:482. CrossRef

895. CamposLC, FranzolinMR, TrabulsiLR. Diarrheagenic Escherichia coli categories among the traditional enteropathogenic E. coli O serogroups–a review. Mem Inst Oswaldo Cruz2004;99:545. CrossRef

896. SpitzJ, YuhanR, KoutsourisA, et al.Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. Am J Physiol1995;268:G374.

897. EstesMK, PrasadBV, AtmarRL. Noroviruses everywhere: has something changed?Curr Opin Infect Dis2006;19:467. CrossRef